US20190290651A1 - Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis - Google Patents
Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis Download PDFInfo
- Publication number
- US20190290651A1 US20190290651A1 US16/436,305 US201916436305A US2019290651A1 US 20190290651 A1 US20190290651 A1 US 20190290651A1 US 201916436305 A US201916436305 A US 201916436305A US 2019290651 A1 US2019290651 A1 US 2019290651A1
- Authority
- US
- United States
- Prior art keywords
- cancer
- inhibitor
- mitosis
- cells
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 139
- 239000003112 inhibitor Substances 0.000 title claims abstract description 115
- 230000011278 mitosis Effects 0.000 title claims abstract description 73
- 238000011282 treatment Methods 0.000 title claims abstract description 51
- 230000008685 targeting Effects 0.000 title abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 93
- 238000000034 method Methods 0.000 claims abstract description 57
- 229930012538 Paclitaxel Natural products 0.000 claims description 48
- 229960001592 paclitaxel Drugs 0.000 claims description 48
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 48
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims description 44
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims description 44
- 230000000694 effects Effects 0.000 claims description 42
- 238000003556 assay Methods 0.000 claims description 33
- 229960004528 vincristine Drugs 0.000 claims description 31
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 31
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 31
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 29
- 229960002066 vinorelbine Drugs 0.000 claims description 29
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 29
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 27
- 229960003668 docetaxel Drugs 0.000 claims description 27
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims description 23
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims description 23
- ZHJGWYRLJUCMRT-QGZVFWFLSA-N 5-[6-[(4-methyl-1-piperazinyl)methyl]-1-benzimidazolyl]-3-[(1R)-1-[2-(trifluoromethyl)phenyl]ethoxy]-2-thiophenecarboxamide Chemical compound O([C@H](C)C=1C(=CC=CC=1)C(F)(F)F)C(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-QGZVFWFLSA-N 0.000 claims description 21
- XQVVPGYIWAGRNI-JOCHJYFZSA-N bi-2536 Chemical compound N1([C@@H](C(N(C)C2=CN=C(NC=3C(=CC(=CC=3)C(=O)NC3CCN(C)CC3)OC)N=C21)=O)CC)C1CCCC1 XQVVPGYIWAGRNI-JOCHJYFZSA-N 0.000 claims description 17
- 206010033128 Ovarian cancer Diseases 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 15
- 206010060862 Prostate cancer Diseases 0.000 claims description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 229960005500 DHA-paclitaxel Drugs 0.000 claims description 12
- 229960001573 cabazitaxel Drugs 0.000 claims description 12
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 12
- LRCZQSDQZJBHAF-PUBGEWHCSA-N dha-paclitaxel Chemical compound N([C@H]([C@@H](OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC)C(=O)O[C@@H]1C(=C2[C@@H](OC(C)=O)C(=O)[C@]3(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]3[C@H](OC(=O)C=3C=CC=CC=3)[C@](C2(C)C)(O)C1)OC(C)=O)C)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 LRCZQSDQZJBHAF-PUBGEWHCSA-N 0.000 claims description 12
- 238000001959 radiotherapy Methods 0.000 claims description 12
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 11
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 11
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 11
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 11
- 201000002528 pancreatic cancer Diseases 0.000 claims description 11
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 238000011284 combination treatment Methods 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- DXOJIXGRFSHVKA-BZVZGCBYSA-N larotaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@@]23[C@H]1[C@@]1(CO[C@@H]1C[C@@H]2C3)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 DXOJIXGRFSHVKA-BZVZGCBYSA-N 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- -1 RPR109881) Chemical compound 0.000 claims description 9
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims description 9
- 229940123237 Taxane Drugs 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 108010056274 polo-like kinase 1 Proteins 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 230000001640 apoptogenic effect Effects 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- MYEJOKLXXLVMPR-STNHEDLKSA-N (ne)-n-[(6e)-6-[2-(1-hydroxypyridin-4-ylidene)ethylidene]cyclohexa-2,4-dien-1-ylidene]-4-methoxybenzenesulfonamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)\N=C(/C=CC=C/1)\C\1=C\C=C1C=CN(O)C=C1 MYEJOKLXXLVMPR-STNHEDLKSA-N 0.000 claims description 6
- QHLVBNKYJGBCQJ-UHFFFAOYSA-N 1-(2-hydroxyethyl)-8-[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy)anilino]-4,5-dihydropyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(OC(F)(F)F)C(NC=2N=C3C=4N(CCO)N=C(C=4CCC3=CN=2)C(N)=O)=C1 QHLVBNKYJGBCQJ-UHFFFAOYSA-N 0.000 claims description 6
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 claims description 6
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 6
- DJNZZLZKAXGMMC-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound COC1=CC(C(=O)NC2CCN(C)CC2)=CC=C1NC(N=C12)=NC=C1N(C)C(=O)C(F)(F)CN2C1CCCC1 DJNZZLZKAXGMMC-UHFFFAOYSA-N 0.000 claims description 6
- JSKUWFIZUALZLX-UHFFFAOYSA-N 5-(5,6-dimethoxy-1-benzimidazolyl)-3-[[2-(trifluoromethyl)phenyl]methoxy]-2-thiophenecarboxamide Chemical compound C1=2C=C(OC)C(OC)=CC=2N=CN1C(SC=1C(N)=O)=CC=1OCC1=CC=CC=C1C(F)(F)F JSKUWFIZUALZLX-UHFFFAOYSA-N 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 6
- GMJWGJSDPOAZTP-MIDYMNAOSA-N bms-188797 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](OC(C)=O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=4C=CC=CC=4)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)OC)C(=O)C1=CC=CC=C1 GMJWGJSDPOAZTP-MIDYMNAOSA-N 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 6
- 229950005692 larotaxel Drugs 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- OCKHRKSTDPOHEN-BQYQJAHWSA-N n-(4-methoxyphenyl)sulfonyl-n-[2-[(e)-2-(1-oxidopyridin-1-ium-4-yl)ethenyl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(C)=O)C1=CC=CC=C1\C=C\C1=CC=[N+]([O-])C=C1 OCKHRKSTDPOHEN-BQYQJAHWSA-N 0.000 claims description 6
- 229950006764 rigosertib Drugs 0.000 claims description 6
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- 229950009016 tesetaxel Drugs 0.000 claims description 6
- 229960003048 vinblastine Drugs 0.000 claims description 6
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 6
- 229960004355 vindesine Drugs 0.000 claims description 6
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 6
- 229960000922 vinflunine Drugs 0.000 claims description 6
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 claims description 6
- 229950003081 volasertib Drugs 0.000 claims description 6
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010038038 rectal cancer Diseases 0.000 claims description 5
- 201000001275 rectum cancer Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 229960002360 vintafolide Drugs 0.000 claims description 5
- KUZYSQSABONDME-QRLOMCMNSA-N vintafolide Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C=4C=CC(NCC=5N=C6C(=O)NC(N)=NC6=NC=5)=CC=4)C(O)=O)C(O)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KUZYSQSABONDME-QRLOMCMNSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 238000010256 biochemical assay Methods 0.000 claims description 3
- 238000000423 cell based assay Methods 0.000 claims description 3
- 206010055114 Colon cancer metastatic Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 abstract description 34
- 229940124597 therapeutic agent Drugs 0.000 abstract description 34
- 239000000203 mixture Substances 0.000 abstract description 6
- 238000011394 anticancer treatment Methods 0.000 abstract description 4
- 229940121849 Mitotic inhibitor Drugs 0.000 abstract description 3
- 230000001613 neoplastic effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 230
- 150000001875 compounds Chemical class 0.000 description 196
- 230000022131 cell cycle Effects 0.000 description 34
- 230000012010 growth Effects 0.000 description 30
- 238000009826 distribution Methods 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 125000003342 alkenyl group Chemical group 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 239000008186 active pharmaceutical agent Substances 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 210000005170 neoplastic cell Anatomy 0.000 description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000035519 G0 Phase Effects 0.000 description 5
- 241000508269 Psidium Species 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 0 *NC1=NC=NC2=C1C1=C(C=C2)N=C(C(=N)O[1*])S1 Chemical compound *NC1=NC=NC2=C1C1=C(C=C2)N=C(C(=N)O[1*])S1 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 201000005787 hematologic cancer Diseases 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000004017 serum-free culture medium Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- CQKBSRPVZZLCJE-UHFFFAOYSA-N n-[2-chloro-5-[(3-chlorophenyl)methylcarbamoyl]phenyl]-2-methoxy-7-oxo-8h-pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound O=C1NC2=NC(OC)=NC=C2C=C1C(=O)NC(C(=CC=1)Cl)=CC=1C(=O)NCC1=CC=CC(Cl)=C1 CQKBSRPVZZLCJE-UHFFFAOYSA-N 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000005059 dormancy Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009093 first-line therapy Methods 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- 102000019075 protein serine/threonine/tyrosine kinase activity proteins Human genes 0.000 description 2
- 108040008258 protein serine/threonine/tyrosine kinase activity proteins Proteins 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- GCSZJMUFYOAHFY-SDQBBNPISA-N (1z)-1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(O)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 GCSZJMUFYOAHFY-SDQBBNPISA-N 0.000 description 1
- BGVLELSCIHASRV-QPEQYQDCSA-N (1z)-1-(3-ethyl-5-methoxy-1,3-benzothiazol-2-ylidene)propan-2-one Chemical compound C1=C(OC)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 BGVLELSCIHASRV-QPEQYQDCSA-N 0.000 description 1
- PGPHHJBZEGSUNE-JYRVWZFOSA-N (5z)-2-anilino-5-(1,3-benzodioxol-5-ylmethylidene)-1h-imidazol-4-one Chemical compound N=1\C(=C/C=2C=C3OCOC3=CC=2)C(=O)NC=1NC1=CC=CC=C1 PGPHHJBZEGSUNE-JYRVWZFOSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- VVZNWYXIOADGSW-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=CC(O)=CC=C2C([N+]([O-])=O)=C1C VVZNWYXIOADGSW-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HAEQAUJYNHQVHV-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylbenzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC2=CC=CC=C2)C=CC=1 HAEQAUJYNHQVHV-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- CHWPNZCMOHHHEH-UHFFFAOYSA-N C=C(C)NC1=CC=C(Cl)C(NC2=NC=NC3=C2C2=C(C=C3)N=C(C(=N)OC)S2)=C1.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl Chemical compound C=C(C)NC1=CC=C(Cl)C(NC2=NC=NC3=C2C2=C(C=C3)N=C(C(=N)OC)S2)=C1.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl CHWPNZCMOHHHEH-UHFFFAOYSA-N 0.000 description 1
- NMRBRALDFAJTCM-UHFFFAOYSA-N C=C(C)NC1=CC=C(Cl)C(NC2=NC=NC3=C2C2=C(C=C3)N=C(C(=N)OC)S2)=C1.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl Chemical compound C=C(C)NC1=CC=C(Cl)C(NC2=NC=NC3=C2C2=C(C=C3)N=C(C(=N)OC)S2)=C1.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl.COC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl NMRBRALDFAJTCM-UHFFFAOYSA-N 0.000 description 1
- IRAIAEWUCLAOLB-UHFFFAOYSA-N CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl Chemical compound CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC(F)=C(C)C=C1Cl.CCOC(=N)C1=NC2=C(S1)C1=C(C=C2)N=CN=C1NC1=CC=C(C)C=C1Cl IRAIAEWUCLAOLB-UHFFFAOYSA-N 0.000 description 1
- VDNZVVPEBHTJCM-UHFFFAOYSA-N CCOC(c1nc(ccc2c3c(Nc(cc(c(F)c4)F)c4Cl)ncn2)c3[s]1)=N Chemical compound CCOC(c1nc(ccc2c3c(Nc(cc(c(F)c4)F)c4Cl)ncn2)c3[s]1)=N VDNZVVPEBHTJCM-UHFFFAOYSA-N 0.000 description 1
- QWDXBWXQLARESL-UHFFFAOYSA-N CCOC(c1nc(ccc2c3c(Nc(ccc(Cl)c4)c4Cl)ncn2)c3[s]1)=N Chemical compound CCOC(c1nc(ccc2c3c(Nc(ccc(Cl)c4)c4Cl)ncn2)c3[s]1)=N QWDXBWXQLARESL-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 101150086683 DYRK1A gene Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 description 1
- 102100023114 Dual specificity tyrosine-phosphorylation-regulated kinase 3 Human genes 0.000 description 1
- 102100023112 Dual specificity tyrosine-phosphorylation-regulated kinase 4 Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 230000020172 G2/M transition checkpoint Effects 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 description 1
- 101001049991 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 3 Proteins 0.000 description 1
- 101001049983 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 4 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000003749 KINOMEscan Methods 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- RLEOCVDWLAYGRX-AUWJEWJLSA-N [(2z)-3-ethyl-2-(2-oxopropylidene)-1,3-benzothiazol-5-yl] acetate Chemical compound C1=C(OC(C)=O)C=C2N(CC)\C(=C\C(C)=O)SC2=C1 RLEOCVDWLAYGRX-AUWJEWJLSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000013061 administrable dose form Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000031016 anaphase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 235000021048 nutrient requirements Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 210000002729 polyribosome Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 230000016853 telophase Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- Cancer cell quiescence effectively a cell in a state of sleep, has been recognized recently as a major mechanism of the resistance of cancer cells to treatments and for providing a pathway for disease recurrence.
- This quiescence alternatively called cellular dormancy, is due to arrest at G 0 phase of the cell cycle.
- a cell enters a cell cycle from gap phase 1 (G 1 ), as shown in FIG. 1 .
- G 1 gap phase 1
- S synthesis phase
- G 2 short pre-mitotic interval
- M mitosis
- a cell can enter cellular dormancy or quiescence, designated as the G 0 phase.
- Cancer cells can either enter an irreversible state before undergoing terminal differentiation, termed senescence, or enter a reversible, true quiescent G 0 state from which they could resume cycling, like quiescent fibroblasts (Coller H A, Sang L, and Roberts J M (2006) A new description of cellular quiescence, PLoS Biology 4, e83).
- a population of cells naturally may be in a quiescent state at any given time and remain quiescent for an indeterminate period until receipt of a signal to enter the cell division cycle.
- the proportion of cancer cells in quiescent state within a population in a tumor may be increased by environmental factors, such as lack of nutrients, hypoxia, high concentration of reactive oxygen species, etc.
- Cells may also be induced into the quiescent state by the action of a drug substance, as in pharmacological quiescence.
- a quiescent cancer cell is resistant to treatments that affect one of more cellular proliferation processes by means of damaging exposed DNA, interfering with DNA replication or repair, interfering with mitosis, or other mechanisms.
- the present invention provides methods and combinations for the treatment of neoplasms that features the targeting of quiescent cancers cells by small molecules, particularly molecules effective against quiescent cancer cells, in combination with treatments known to be effective against certain neoplastic cells.
- the present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
- the invention features a method of treating a neoplasm comprising: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent effective against quiescent cancer cells; and (b) second agent which is an inhibitor of mitosis, wherein the two agents can be administered sequentially or concomitantly.
- the neoplasm is a cancer or a population of cancer cells in vitro or in vivo.
- the subject receiving the treatment is diagnosed with cancer (e.g., metastatic or pre-metastatic).
- the subject has been previously treated with a first-line therapy against cancer.
- the subject is treated, or has been treated, with two or more inhibitors of mitosis sequentially or concomitantly.
- the combined treatment may result in improved outcomes, such as increased survival, reduction of severity, delay or elimination of recurrence, or reduced side effects of the primary treatments (i.e., the inhibitor of mitosis).
- the second agent is administered at lower dose and/or for a shorter duration when administered as part of the combination as compared to a treatment with the agent alone.
- the EC 50 value of the inhibitor of mitosis is at least 20% lower in the combination treatment when compared to the same treatment with the inhibitor of mitosis alone, as determined, for example, in cell-based assays.
- the combination treatment increases fraction of apoptotic cells in a treated population as compared to either agent alone, by at least by 2-fold as determined, for example, by fraction of sub-G 0 cells by FACS assay.
- the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor.
- the DYRK1 inhibitor is a compound that inhibits activity of a DYRK1 kinase, either DYRK1A or DYRK1B (in vitro or in vivo), for example, with an IC 50 of 100 nM or lower in biochemical assays.
- the DYRK1 inhibitor reduces the fraction of quiescent cancer cells (in vitro or in vivo) that would otherwise be found in the absence of such inhibitor, for example, by at least 10%.
- the DYRK1 inhibitor inhibits both DYRK1A and DYRK1B.
- the DYRK1 inhibitor is selective for DYRK1A or DYRK1B.
- the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor.
- the DYRK1 inhibitor is a compound of formula I:
- R 1 is a substituted or unsubstituted C 1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl
- R 2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO 2 , NHC(O)C 1-4 alkyl, C 1-4 alkyl, OH, OC 1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S.
- the compound of formula I is selected from:
- the methods of the invention further provide (c) administering to the subject another cancer therapy, for example, radiation therapy or other cancer treatment.
- another cancer therapy for example, radiation therapy or other cancer treatment.
- the methods of the invention comprise: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent of formula I; (b) an inhibitor of mitosis; and (c) radiation therapy; each therapy being administered sequentially or concomitantly.
- the subject is first treated with radiation therapy, whereupon the subject is administered a therapeutic agent of Formula I, alone or in combination with the inhibitor of mitosis.
- the subject is co-administered (a) the therapeutic agent effective against quiescent cancer cells, (b) the inhibitor of mitosis and, optionally, (c) the radiation therapy.
- the inhibitor of mitosis is an inhibitor of mitosis effective to treat or prevent a neoplasm, including but not limited to, all such compounds approved for the treatment of cancer and compounds that otherwise demonstrate efficacy in treating cancer in mammalian subject (e.g., mice, rats, dogs, monkeys, humans), and compounds that demonstrate efficacy against neoplastic cells in vitro. Many such compounds are known.
- the inhibitor of mitosis is a taxane.
- the taxane inhibitor of mitosis is, for example, BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
- the inhibitor of mitosis is a vinca alkaloid.
- the vinca alkaloid inhibitor of mitosis is, for example, vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.
- the vinca alkaloid inhibitor of mitosis is vintafolide.
- the inhibitor of mitosis is a PLK1 inhibitor.
- the PLK1 inhibitor of mitosis is, for example, BI-2536, GSK 461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
- the inhibitor of mitosis is BI-2536 or GSK461364.
- the neoplasm being treated is a cancer, for example, biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer (e.g. melanoma), testicular cancer, thyroid cancer, or uterine cancer.
- the neoplasm being treated is a bladder cancer, breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, and prostate cancer.
- the cancer is primary or metastatic.
- the cancer is of the type represented by the cell line types shown in the Examples.
- the embodiments are not meant to be limiting with regard to additional combination components, especially therapeutic agents and inhibitors that are part of existing treatment combinations, such as, for example, TPF wherein T stands for Taxotere®, that is docetaxel, or PCV wherein V stands for vincristine sulfate.
- TPF wherein T stands for Taxotere®, that is docetaxel
- PCV wherein V stands for vincristine sulfate.
- the embodiments are not meant to be limiting with regard to routes and order of administration or with regard to patient type (previously untreated or previously treated, absence or presence of co-morbid conditions, sex, etc.) or stage of patient's disease, type of inhibitor of mitosis, etc.
- FIG. 1 shows a schematic diagram of a mitotic cycle of a eukaryotic cell.
- FIG. 2 shows a schematic diagram of a mitotic cycle of a eukaryotic cancer cell annotated to indicate the stages of the cell cycle upon which some of the available anti-cancer therapeutic agents are believed act.
- FIG. 3 shows effect of combination of paclitaxel and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of SW620 cells.
- FIG. 4 shows effect of combination of paclitaxel and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 5 shows effect of combination of paclitaxel and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of LNCap cells.
- FIG. 6 shows effect of combination of paclitaxel and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of HCC827 cells.
- FIG. 7 shows effect of combination of paclitaxel and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of A549 cells.
- FIG. 8 shows effect of combination of paclitaxel and Compound I-7 (0, 2, 4, 8, and 10 ⁇ M) on the growth of SK-OV-3 cells.
- FIG. 9 shows effect of combination of paclitaxel and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of OVCAR3 cells.
- FIG. 10 shows effect of combination of docetaxel and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of SW620 cells.
- FIG. 11 shows effect of combination of docetaxel and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 12 shows effect of combination of docetaxel and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of HCC827 cells.
- FIG. 13 shows effect of combination of docetaxel and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of A549 cells.
- FIG. 14 shows effect of combination of docetaxel and Compound I-7 (0, 4, and 8 ⁇ M) on the growth of SK-OV-3 cells.
- FIG. 15 shows effect of combination of docetaxel and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of OVCAR3 cells.
- FIG. 16 effect of combination of vincristine and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 17 shows effect of combination of vincristine and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of H1975 cells.
- FIG. 18 shows effect of combination of vincristine and Compound I-7 (0, 4, and 8 ⁇ M) on the growth of SK-OV-3 cells.
- FIG. 19 shows effect of combination of vincristine and Compound I-7 (0, 1, and 3 ⁇ M) on the growth of OVCAR3 cells.
- FIG. 20 shows effect of combination of vinorelbine and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 21 shows effect of combination of vinorelbine and Compound I-5 (0, 2, and 4 ⁇ M) on the growth of H1975 cells.
- FIG. 22 shows effect of combination of vinorelbine and Compound I-7 (0, 1, and 3 ⁇ M) on the growth of OVCAR3 cells.
- FIG. 23 shows effect of combination of vincristine and Compound I-7 (0, 4, and 8 ⁇ M) on the growth of SK-OV-3 cells.
- FIG. 24 shows effect of combination of vincristine and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of A549 cells.
- FIG. 25 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of H1975 cells.
- FIG. 26 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of PANC1 cells.
- FIG. 27 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 28 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of A549 cells.
- FIG. 29 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of H1975 cells.
- FIG. 30 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of PANC1 cells.
- FIG. 31 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 ⁇ M) on the growth of DMS273 cells.
- FIG. 32 shows effect of combination of GSK461364 and Compound I-7 (0, 3, and 6 ⁇ M) on the growth of A549 cells.
- FIG. 33 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS ⁇ media; Panel C: FBS+ media with 4 ⁇ M Compound I-7; Panel D: FBS+ media with 2.7 nM paclitaxel; Panel E: FBS+ media with 5 ⁇ M Compound I-7 and 2 nM paclitaxel.
- FIG. 34 shows FACS analyses of cell cycle distribution of SW620 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS ⁇ media; Panel C: FBS+ media with 4 ⁇ M Compound I-7; Panel D: FBS+ media with 2 nM paclitaxel; Panel E: FBS+ media with 4 ⁇ M Compound I-7 and 2 nM paclitaxel.
- FIG. 35 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS ⁇ media; Panel C: FBS+ media with 4 ⁇ M Compound I-7; Panel D: FBS+ media with 1.1 nM vincristine; Panel E: FBS+ media with 4 ⁇ M Compound I-7 and 1.1 nM vincristine.
- FIG. 36 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS ⁇ media; Panel C: FBS+ media with 4 ⁇ M Compound I-7; Panel D: FBS+ media with 8.1 nM vinorelbine; Panel E: FBS+ media with 4 ⁇ M Compound I-7 and 8.1 nM vinorelbine.
- FIG. 37 FACS analyses by DNA content of cell cycle distribution of SW620 cells. The cells were incubated in Panel A: 24 hours in FBS ⁇ media; Panel B: 24 hours in FBS ⁇ media with 2.5 ⁇ M AZ191; Panel C: 24 hours in FBS ⁇ media with 5 ⁇ M AZ191; Panel D: 24 hours in FBS ⁇ media with 10 ⁇ M AZ191.
- FIG. 38 shows FACS analyses by DNA content of cell cycle distribution of SW620 cells.
- the cells were incubated in Panel A: 24 hours in FBS ⁇ media with DMSO control;
- Panel B 24 hours in FBS ⁇ media with 1.25 ⁇ M Compound I-7;
- Panel C 24 hours in FBS ⁇ media 2.5 ⁇ M Compound I-7;
- Panel D 24 hours in FBS ⁇ media with 5 ⁇ M Compound I-7.
- an “alkyl” group is a saturated, straight or branched, hydrocarbon group, comprising from 1 to 8 carbon atoms (C 1-8 alkyl group), in particular from 1 to 6, or from 1 to 4 carbons atoms, unless otherwise indicated.
- alkyl groups having from 1 to 6 carbon atoms inclusive are methyl, ethyl, propyl (e.g., n-propyl, iso-propyl), butyl (e.g., tert-butyl, sec-butyl, n-butyl), pentyl (e.g., neo-pentyl), hexyl (e.g., n-hexyl), 2-methylbutyl, 2-methylpentyl and the other isomeric forms thereof.
- propyl e.g., n-propyl, iso-propyl
- butyl e.g., tert-butyl, sec-butyl, n-butyl
- pentyl e.g., neo-pentyl
- hexyl e.g., n-hexyl
- 2-methylbutyl 2-methylpentyl and the other isomeric forms thereof
- Alkyl groups may be unsubstituted or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- an “alkenyl” group is a straight or branched hydrocarbon group comprising at least one double carbon-carbon bond, comprising from 2 to 8 carbon atoms (unless otherwise indicated).
- alkenyl groups containing from 2 to 6 carbon atoms are vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl and the isomeric forms thereof.
- Alkenyl groups may be unsubstituted, or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- an “alkynyl” group is a straight or branched hydrocarbon group comprising at least one triple carbon-carbon bond, comprising from 2 to 8 carbon atoms.
- Alkynyl groups may be substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- an “aryl” group is an aromatic hydrocarbon cycle, comprising from 5 to 14 carbon atoms. Most preferred aryl groups are mono- or bi-cyclic and comprises from 6 to 14 carbon atoms, such as phenyl, alpha-naphtyl, 3-naphtyl, antracenyl, preferably phenyl. “Aryl” groups also include bicycles or tricycles comprising an aryl cycle fused to at least another aryl, heteroaryl, cycloalkyl or heterocycloalkyl group, such as benzodioxolane, benzodioxane, dihydrobenzofurane or benzimidazole.
- Aryl groups may be unsubstituted, or substituted by at least one (e.g. 1, 2 or 3) group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- aryl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- halogen atom or “halo” is a Cl, Br, F, or I atom.
- an “alkoxyl” group is an alkyl group linked to the rest of the molecule through an oxygen atom, of the formula O-alkyl.
- an “amino” group is a NH 2 , NH-alkyl, or N(alkyl) 2 group.
- a “heteroaryl” group is an aryl group whose cycle is interrupted by at least at least one heteroatom, for example a N, O, or S, atom, such as thiophene or pyridine.
- Heteroaryl groups may be unsubstituted, or substituted by at least one (e.g. 1, 2 or 3) group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro and amino groups.
- heteroaryl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- a “cycloalkyl” denotes a saturated alkyl group that forms one cycle having preferably from 3 to 14 carbon atoms, and more preferably 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may be unsubstituted or substituted by at least one (e.g.
- 1, 2 or 3 group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- cycloalkyl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- a “heterocycloalkyl” group is a cycloalkyl group comprising at least one heteroatom, such as pyrrolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, pyran, dioxin, morpholine or piperazine.
- a heterocycloalkyl group may in particular comprise from four to fourteen carbon atoms, such as morpholinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, dithiolanyl.
- Heterocycloalkyl groups may be unsubstituted, or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro and amino groups.
- heterocycloalkyl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- a “neoplasm” means an abnormal mass of tissue that results from neoplasia.
- “Neoplasia” means a process of an abnormal proliferation of cells.
- a neoplasm is a solid cancer, or alternately a hematopoietic cancer.
- the neoplasia may be benign, pre-malignant, or malignant.
- neoplasm encompasses mammalian cancers, in some embodiments, human cancers, and carcinomas, sarcomas, blastomas of any tissue (for example adenocarcinomas, squamous cell carcinoma, osteosarcomas, etc.), germ cell tumors, glial cell tumors, lymphomas, leukemias, including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, rectal, pancreatic, stomach, brain, head and neck, skin, uterine, cervical, testicular, esophagus, thyroid, biliary cancer, liver cancer, and cancer of the bone and cartilaginous tissue, including non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas) and Hodgkin's lymphoma, leukemia, multiple myeloma, and myelodysplastic syndrome.
- non-Hodgkin's lymphomas
- the terms “treat,” “treating,” or “treatment,” mean to counteract a medical condition (e.g., cancer) to the extent that the medical condition is improved according to a clinically-acceptable standard. Improvement in cancer can include: 1) reduced rate of tumor growth (tumor growth inhibition), 2) tumor shrinkage (regression), 3) remission, whether partial or total, 4) reduction in metastases, 5) prolonging progression free survival, and 6) delay or elimination of recurrence.
- a medical condition e.g., cancer
- Improvement in cancer can include: 1) reduced rate of tumor growth (tumor growth inhibition), 2) tumor shrinkage (regression), 3) remission, whether partial or total, 4) reduction in metastases, 5) prolonging progression free survival, and 6) delay or elimination of recurrence.
- treating includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the cancer mass, or volume, or the malignant cell count; ameliorating or improving a clinical symptom or indicator associated with solid cancers or hematopoietic cancers; delaying, inhibiting, or preventing the progression of solid cancers or hematopoietic cancers; or partially or totally delaying, inhibiting or preventing the onset or development of solid cancers or hematopoietic cancers. “Treatment” also can mean prolonging survival compared to expected survival without treatment or compared to standard of care treatment.
- Treating includes prophylactic or preventative treatment.
- “Prophylactic treatment” refers to treatment before appearance or re-appearance of clinical symptoms of a target disorder to prevent, inhibit, or reduce its occurrence, severity, or progression.
- an “effective amount” refers to an amount of a therapeutic agent or a combination of therapeutic agents that is therapeutically or prophylactically sufficient to affect the desired improvement in the targeted disorder.
- Examples of effective amounts typically range from about 0.0001 mg/kg of body weight to about 500 mg/kg of body weight per single administered dose, such doses being administered once or over a period of time.
- An example range is from about 0.0001 mg/kg of body weight to about 5 mg/kg per dose. In other examples, the range can be from about 0.0001 mg/kg to about 5 mg/kg per single administered dose.
- effective amounts range from about 0.01 mg/kg of body weight to 50 mg/kg of body weight per single administered dose, or from 0.01 mg/kg of body weight to 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, or 40 mg/kg of body weight per single administered dose.
- an example of an effective dose is that amount approved of by a regulatory agency for treatment of an indication.
- the term “subject” refers to a mammal, for example a human, but can also mean an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like), and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- companion animals e.g., dogs, cats, and the like
- farm animals e.g., cows, sheep, pigs, horses, and the like
- laboratory animals e.g., rats, mice, guinea pigs, and the like.
- the term “therapeutic agent” means any chemical molecule used or contemplated for use or investigated for use in cancer treatment, including cytotoxic, cytostatic, or targeted agents, whether small molecules, or peptides, or antibodies, or oligonucleotides, irrespective of mechanism of action.
- the terms “therapeutic” or “therapeutic agent” refer to either the active pharmaceutical ingredient (API) or its pharmaceutically acceptable salt or hydrate (solvate), or a drug product containing the therapeutic agent, however formulated, and whether API is amorphous or crystalline and of whatever polymorphic form.
- Formulation means a combination of an active pharmaceutical ingredient (API, drug substance) or ingredients (APIs) combined with excipients and/or delivery vehicle to make an administrable dosage form (drug product).
- API active pharmaceutical ingredient
- APIs ingredients
- excipients and/or delivery vehicle to make an administrable dosage form (drug product).
- a reference to paclitaxel includes Taxol®, Abraxane®, Lipusu®, and any other drug product with paclitaxel as the active ingredient.
- the therapeutic agents of the invention can be administered alone, but are generally administered with a pharmaceutically acceptable carrier, with respect to standard pharmaceutical practice (such as described in Remington's Pharmaceutical Sciences, Mack Publishing). Accordingly, a further object of this invention relates to pharmaceutical compositions defined herein and pharmaceutically acceptable carriers.
- inhibitor means any composition that reduces the activity of an enzyme.
- An example of an inhibitor is a chemical molecule.
- a measure of the potency of an inhibitor is its “50% inhibitory concentration” (IC 50 ).
- IC 50 concentration or IC 50 value is the concentration of an inhibitor at which 50% of the enzymatic activity is inhibited by the inhibitor.
- kinase inhibitors are known to persons of ordinary skill in the art and include direct and indirect functional assays, such as the HotSpotTM kinase assay technology (Reaction Biology Corporation, Malvern, Pa., www.reactionbiology.com) or competition binding assays, such as KINOMEscan® (DiscoverX Corporation, Freemont, Calif., www.discoverx.com).
- direct and indirect functional assays such as the HotSpotTM kinase assay technology (Reaction Biology Corporation, Malvern, Pa., www.reactionbiology.com) or competition binding assays, such as KINOMEscan® (DiscoverX Corporation, Freemont, Calif., www.discoverx.com).
- EC 50 concentration or EC 50 value is the concentration of a drug that produces half-maximal response, such as, for example, 50% growth inhibition or 50% reduction in cell viability.
- the term “quiescence” or “quiescent state” refers to the G 0 state of the cell cycle, as understood by the practitioners of the art.
- the term “therapeutic agent effective against quiescent cancer cells” refers to a molecule that either reduces the fraction of quiescent cancer cells in a cell population or prevents, completely or substantially, an increase in fraction of quiescent cancer cells in a cell population under conditions that otherwise would lead to such an increase.
- a “quiescent neoplastic cell”, alternately referred to as a “quiescent cancer cell” means a cancer cell that exists in the quiescent, or G 0 , state of the cell cycle.
- a “fraction of quiescent neoplastic cells” or “fraction of quiescent cancer cells”, as used herein, means the portion of a cancer cell population that exists in the G 0 state of the cell cycle. Determining the fraction of quiescent neoplastic cells includes characterizing a cell population by distribution of its constituent cells within the stages of the cell cycle. The fraction of cells in the G 0 state (i.e., quiescent neoplastic cells) is quantified relative to the total cell population. The fraction may be expressed as a percentage of the total cell population (i.e.
- Characterization of the cell population by distribution of its constituent cells within the stages of the cell cycle may be achieved by techniques known to persons of ordinary skill in the art, and may include analysis by DNA and/or RNA content using flow cytometry methods, for example, fluorescence-activated cell sorting (FACS).
- FACS fluorescence-activated cell sorting
- the present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancers cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents which are inhibitors of mitosis.
- the invention features a method of treating a neoplasm comprising: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent effective against quiescent cancer cells; and (b) second agent which is an inhibitor of mitosis, wherein the two agents can be administered sequentially or concomitantly.
- the neoplasm is a cancer or a population of cancer cells in vitro or in vivo.
- the subject receiving the treatment is diagnosed with cancer (e.g., metastatic or pre-metastatic).
- the subject has been treated previously with a first-line therapy against cancer.
- the subject has been treated previously with second-line and/or other therapies.
- the subject is treated, or has been treated, with radiation therapy.
- the subject was treated with surgery, for example to resect or de-bulk a tumor.
- the subject's neoplasm has recurred.
- the subject is treated, or has been treated, with two or more inhibitor of mitosis sequentially or concomitantly.
- the combined treatment may result in improved outcomes, such as increased survival, reduction of severity, delay or elimination of recurrence, or reduced side effects of the primary treatments (i.e., the inhibitor of mitosis).
- the second agent is administered at lower dose and/or for a shorter duration when administered as part of the combination as compared to a treatment with the agent alone.
- the EC 50 value of the inhibitor of mitosis is at least 20%, 25%, 30%, 40%, 50%, 100%, 3-fold, 5-fold, 10-fold lower in the combination treatment when compared to the same treatment with the first agent, as determined, for example, in cell-based assays.
- the combination treatment increases fraction of apoptotic cells in a treated population as compared to either agent alone, by at least by 2-fold, 3-fold, 4-fold, 5-fold as determined, for example, by fraction of sub-G 0 phase cells in a FACS assay.
- the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor.
- the DYRK1 inhibitor is a compound that inhibits activity of a DYRK1 kinase, either DYRK1A or DYRK1B (in vitro or in vivo), for example, with an IC 50 value of ⁇ 100 nM, ⁇ 90 nM, ⁇ 80 nM, ⁇ 70 nM, ⁇ 60 nM, ⁇ 50 nM, ⁇ 40 nM, ⁇ 30 nM, ⁇ 20 nM, ⁇ 10 nM, ⁇ 5 nM or lower in biochemical assays.
- the DYRK1 inhibitor reduces the fraction of quiescent cancer cells (in vitro or in vivo) in a population or a tumor that would otherwise be found in the absence of such inhibitor, for example, by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or more.
- the DYRK1 inhibitor inhibits both DYRK1A and DYRK1B.
- the DYRK1 inhibitor is selective for DYRK1A, with ratio of DYRK1B IC 50 to DYRK1A IC 50 of 1000, 100, 50, 25, 10 to 1.
- the DYRK1 inhibitor is selective for DYRK1B, with ratio of DYRK1A IC 50 to DYRK1B IC 50 of 1000, 100, 50, 25, 10, or 5 to 1.
- the DYRK1 inhibitor is selective for DYRK1 by at least 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold as compared to DYRK2 and/or DYRK3 and/or DYRK4, as determined by ratios of IC 50 values. In some embodiments, the DYRK1 inhibitor is selective for DYRK1 by at least 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 500-fold, 1000-fold as compared to cyclin dependent kinases (CDKs) such, as for example, CDK2, as determined by ratios of IC 50 values.
- CDKs cyclin dependent kinases
- DYRK1 inhibitors examples include AZ191, DYRKi, harmine, ID-8, leucettine L41, NCGC00185981, INDY, ProINDY, TC-S 7004, and TG003.
- At least one known DYRK1 inhibitor, TC-S 7004, (US20120184562) is reported to be effective against quiescent cancer cells in vitro (Ewton D Z, Hu J, Vilenchik M, Deng X, Luk K C, Polonskaia A, Hoffman A F, Zipf K, Boylan J F, and Friedman E A. (2011) Inactivation of MIRK/DYRK1B kinase targets quiescent pancreatic cancer cells. Molecular Cancer Therapeutics 10: 2104-2114).
- the DYRK1 inhibitor is a compound of formula I:
- R 1 is a substituted or unsubstituted C 1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl
- R 2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO 2 , NHC(O)C 1-4 alkyl, C 1-4 alkyl, OH, OC 1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S.
- the compound of formula I is selected from:
- the methods of the invention further provide (c) administering to the subject another cancer therapy, for example, radiation therapy or other cancer treatment.
- another cancer therapy for example, radiation therapy or other cancer treatment.
- the methods of the invention comprise: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent of formula I; (b) an inhibitor of mitosis; and (c) radiation therapy; each therapy being administered sequentially or concomitantly.
- the subject is first treated with radiation therapy, whereupon the subject is administered a therapeutic agent of Formula I, alone or in combination with the inhibitor of mitosis.
- the subject is co-administered (a) the therapeutic agent effective against quiescent cancer cells, (b) the inhibitor of mitosis, and, optionally (c) the radiation therapy.
- the inhibitor of mitosis is an inhibitor of mitosis effective to treat or prevent a neoplasm, including but not limited to, all such compounds approved for the treatment of cancer, compounds in clinical trials for the treatment of cancer, compounds that otherwise demonstrate efficacy in treating cancer in mammalian subject (e.g., mouse, rats, monkeys, humans), and compounds that demonstrate efficacy against neoplastic cells in vitro. Many such compounds are known.
- the inhibitor of mitosis is a taxane.
- Taxanes useful for the methods of the invention include BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
- the inhibitor of mitosis is a vinca alkaloid.
- Vinca alkaloids useful for the methods of the invention include vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.
- the vinca alkaloid inhibitor of mitosis is vintafolide.
- the inhibitor of mitosis is a PLK1 inhibitor.
- PLK1 inhibitors useful for the methods of the invention include BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
- the inhibitor of mitosis is BI-2536 or GSK461364.
- a neoplasm is biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer (e.g. melanoma), testicular cancer, thyroid cancer, or uterine cancer.
- the neoplasm is selected from bladder cancer, breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, and prostate cancer.
- the cancer is primary or metastatic.
- the cancer is of the type represented by the cell line types shown in the Examples.
- the embodiments are not meant to be limiting with regard to additional combination components, especially compounds that are part of existing treatment combinations, such as, for example, TPF wherein T stands for Taxotere®, that is docetaxel, or PCV wherein V stands for vincristine sulfate.
- TPF Taxotere®
- PCV vincristine sulfate
- the embodiments described here are illustrative and are not meant to be limiting with regard to routes and order of administration, patient type (previously untreated or previously treated, absence or presence of co-morbid conditions, age, sex, etc.), or stage of patient's disease, type of inhibitor of mitosis, etc.
- Inhibitors of mitosis are known in the art (Dominguez-Brauer C, et al, (2015) Targeting mitosis in cancer: emerging strategies, Molecular Cell 60, 524-536). As used herein, the terms “inhibitor of mitosis” and “mitotic inhibitor” are equivalent and may be used interchangeably.
- An inhibitor of mitosis interrupts cell cycling during the M phase or at a checkpoint entering (the G 2 /M checkpoint) or leaving (the post-mitotic checkpoint) the M phase. In M phase, the chromosomes and cytoplasm are divided into two daughter cells (cytokinesis).
- Mitosis proceeds in five phases: prophase, prometaphase, metaphase, anaphase, and telophase and an inhibitor of mitosis can interrupt any of these phases.
- inhibitors of mitosis include taxanes, vinca alkaloids, and PLK1 inhibitors.
- taxanes include BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927);
- vinca alkaloids include vincristine, vinblastine, vindesine, vinflunine, and vinorelbine;
- PLK1 inhibitors include BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
- DYRK1 kinases such as DYRK1A and DYRK1B, may be important for the maintenance of cancer cells in G 0 state (quiescent state).
- DYRK1B/Mirk is a member of the Minibrain/DYRK family of kinases which mediates survival and differentiation in certain normal tissues.
- Dyrk a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII, Journal of Biological Chemistry 271, 3488-3495; Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor F J, and Joost H G (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases, Journal of Biological Chemistry 273, 25893-25902).
- DYRK1B is expressed at detectable levels in skeletal muscle cells and testes. Knockout of DYRK1B caused no evident abnormal phenotype in mice even in developing muscle, suggesting that DYRK1B is not an essential gene for normal development. Supporting this interpretation, normal fibroblasts exhibited no alteration in survival after 20-fold depletion of DYRK1B kinase levels. Thus, DYRK1B does not appear to be an essential gene for survival of normal cells yet there is evidence that it is upregulated in certain malignant cancer cells in which DYRK1B is believed to mediate survival by retaining cancer cells in quiescent state. These unusual characteristics suggest that DYRK1B may be an attractive target for therapeutic intervention and in particular for anti-cancer therapy directly against quiescent cancer cells.
- the disclosed combinations and methods may afford one or more of the improvements as defined in the Glossary relative to the use of each individual components or existing single and combination treatments. Also, the disclosed combinations and methods may permit reduction in doses and/or frequency of administration of therapeutic agents and radiation to achieve the same improvements as a result of treatment relative to what is possible using individual components or existing single and combination treatments.
- the disclosed combinations need not be synergistic to yield a significant improvement in the effectiveness of treatment relative to single therapy with an inhibitor of mitosis.
- quiescent cancer cells are inherently less susceptible to anti-cancer therapeutics, including mitotic inhibitors, and even a small fraction of quiescent cells that survives post treatment can lead to recurrence. Consequently, eradicating the resistant, quiescent cell populations in a neoplasm may or may not yield a synergistic reduction in EC 50 values yet may yield a significant improvement in cancer recurrence and appearance of metastatic neoplasms.
- the administration regimen and routes of administration of the disclosed combinations may well vary depending on the neoplasm treated, extent of progression of the neoplasm, exact combination selected, age, sex, and physical condition of the subject, and other factors. Administration regimen may include multiple doses per period of time, the treatments administered concurrently or sequentially, etc. Furthermore, the combinations may be administered to subjects who are naive to treatment (have not been treated), or subjects who underwent previous treatments, or have undergone surgical resection or debulking of a solid tumor, or subjects whose cancers relapsed. For example, therapeutic agent effective against quiescent cancer cells may be administered before the inhibitor of mitosis.
- the therapeutic agent effective against quiescent cancer cells may be administered 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, one week before the inhibitor of mitosis.
- the therapeutic agent effective against quiescent cancer cells may be administered at the same time (concomitantly) as the inhibitor of mitosis.
- the therapeutic agent effective against quiescent cancer cells may be administered 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours after the inhibitor of mitosis.
- the therapeutic agent effective against quiescent cancer cells and/or the inhibitor of mitosis may be administered before, after, or concomitantly with radiation or other therapy.
- the therapeutic agent effective against quiescent cancer cells may be administered daily, every two days, every three days, every four days, once weekly, once every two weeks, once per month by oral, intravenous (IV), intraperitoneal (IP), subcutaneous (SC), intratumoral (IT), intrathecal, or other routes of administration.
- IV intravenous
- IP intraperitoneal
- SC subcutaneous
- I intratumoral
- intrathecal or other routes of administration.
- the combinations may be administered to subjects who are naive to treatment (have not been treated), or subjects who underwent previous treatments with first-line, second-line, third-line, or other therapies, radiation treatments, or have undergone surgical resection or debulking of a solid tumor, or subjects whose cancers relapsed, or subjects whose cancers are non-metastatic or metastatic.
- DMS273 small cell lung cancer cell line
- H1975 non-small cell lung cancer cell line harboring L858R and T790M mutations in EGFR TK
- A549 a non-small cell lung cancer cell line with wild type EGFR
- LNCap prostate cancer cell line
- SW620 colon cancer cell line
- MiaPaCa2 pancreatic cancer cell line
- PANC1 pancreatic cancer cell line
- OVCAR3 ovarian cancer cell line
- SK-OV-3 ovarian cancer cell line.
- Cell cultures were seeded into 6-well plates at 3 ⁇ 10 5 -6 ⁇ 10 5 cells/well; the plated number of cells depended on cell size and rate of proliferation, aiming for approximately 50% confluency. After seeding, the cells were allowed to attach for 24 hours while incubated at 37° C. in a humidified 5% CO 2 atmosphere, and then treated with compounds for desired amount of time (usually 24 hours) incubating under same conditions. Then the cells were harvested by trypsinization, pooled with the floating cells, washed in PBS, and fixed in 70% ice-cold ethanol overnight.
- AO staining For Acridine Orange (AO) staining, fixed cells were washed once with ice-cold PBS, re-suspended in 100 ⁇ L PBS, followed by addition of 200 ⁇ L of permeabilizing solution and 600 ⁇ L AO staining solution. The measurements were performed with Guava easyCyte HT flow cytometer (EMD Millipore) using the blue laser for excitation at 488 nm, monitoring emission of the AO-DNA complex at 526 nm and AO-RNA complex at 650 nm. The complete protocol and composition of buffers are described in the literature (Darzynkiewicz Z, Juan G, and Srour E F (2004) Differential Staining of DNA and RNA (2004). Current Protocols in Cytometry , Chapter 7:Unit 7.3).
- cells were seeded into 96-well plates at 2 ⁇ 10 3 -6 ⁇ 10 3 cells/well; the plated number of cells depended on cell size and rate of proliferation aiming for approximately 50% confluency. After seeding, the cells were allowed to attach for 24 hours incubated at 37° C. in a humidified 5% CO 2 atmosphere.
- the treatments were performed using at least 6 different concentrations of a compound in 1:3 serial dilutions in DMSO such that the DMSO concentration in the cell medium was ⁇ 1%.
- the cell cultures were incubated for an additional 96 hours in 5% CO 2 incubator at 37° C. Treatments were performed in triplicate. Results were analyzed by CellTiter-GloTM Luminescent Cell Viability Assay (Promega, cat. # G7571) according to the manufacturer's instructions using Spectra MAX Gemini Spectrophotometer (Molecular Devices).
- SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 100 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 accordingly.
- the observed EC 50 values of paclitaxel were 8.1 nM when Compound I-5 was not present, 2.3 nM when Compound I-5 was present at a concentration of 2 and 0.2 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 3 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of paclitaxel were 2.7 nM when Compound I-7 was not present, 1.9 nM when Compound I-7 was present at a concentration of 2 ⁇ M, and 0.9 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 4 .
- LNCap cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of paclitaxel were 3.2 nM when Compound I-5 was not present, 2.1 nM when Compound I-5 was present at a concentration of 2 ⁇ M, and 0.9 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 5 .
- HCC827 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of paclitaxel were 4.2 nM when Compound I-7 was not present, 2.5 nM when Compound I-7 was present at a concentration of 3 ⁇ M, and 0.6 nM when Compound I-7 was present at a concentration of 6 ⁇ M. See FIG. 6 .
- A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of paclitaxel were 4.8 nM when Compound I-7 was not present, 2.5 nM when Compound I-7 was present at a concentration of 3 ⁇ M, and 0.7 nM when Compound I-7 was present at a concentration of 6 ⁇ M. See FIG. 7 .
- SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 ⁇ M, 4 ⁇ M, 8 ⁇ M, and 10 ⁇ M.
- the observed EC 50 values of paclitaxel were 9.7 nM when Compound I-7 was not present, 9.4 nM when Compound I-7 was present at a concentration of 2 ⁇ M, 4.8 nM when Compound I-7 was present at a concentration of 4 ⁇ M, 4.7 nM when Compound I-7 was present at a concentration of 8 ⁇ M, and 5.2 nM when Compound I-7 was present at a concentration of 10 ⁇ M. See FIG. 8 .
- OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of paclitaxel were 3.3 nM when Compound I-7 was not present, 2.8 nM when Compound I-7 was present at a concentration of 3 ⁇ M, and 1.7 nM when Compound I-7 was present at a concentration of 6 ⁇ M. See FIG. 9 .
- SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 100 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of docetaxel were 2.85 nM when Compound I-5 was not present, 0.69 nM when Compound I-5 was present at a concentration of 2 and ⁇ 0.015 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 10 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of docetaxel were 0.64 nM when Compound I-7 was not present, 0.38 nM when Compound I-7 was present at a concentration of 2 and 0.14 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 11 .
- HCC827 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of docetaxel were 1.8 nM when Compound I-7 was not present, 0.6 nM when Compound I-7 was present at a concentration of 2 and 0.03 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 12 .
- A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 5 nM and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of docetaxel were 1.4 nM when Compound I-7 was not present, 0.6 nM when Compound I-7 was present at a concentration of 2 and 0.1 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 13 .
- SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 4 ⁇ M and 8 ⁇ M.
- the observed EC 50 values of docetaxel were 2.5 nM when Compound I-7 was not present, 1.5 nM when Compound I-7 was present at a concentration of 2 and 0.3 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 14 .
- OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of docetaxel were 0.85 nM when Compound I-7 was not present, 0.52 nM when Compound I-7 was present at a concentration of 2 and ⁇ 0.04 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 15 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vincristine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vincristine were 1.1 nM when Compound I-5 was not present, 0.4 nM when Compound I-5 was present at a concentration of 2 and ⁇ 0.04 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 16 .
- H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vincristine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vincristine were 1.5 nM when Compound I-5 was not present, 0.85 nM when Compound I-5 was present at a concentration of 2 and 0.35 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 17 .
- SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vincristine used in this assay was 20 nM and the concentrations of Compound I-7 were 4 ⁇ M and 8 ⁇ M.
- the observed EC 50 values of vincristine were 8.7 nM when Compound I-7 was not present, 2.1 nM when Compound I-7 was present at a concentration of 4 and 1.0 nM when Compound I-7 was present at a concentration of 8 ⁇ M. See FIG. 18 .
- OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vincristine used in this assay was 1 nM and the concentrations of Compound I-7 were 1 ⁇ M and 3 ⁇ M.
- the observed EC 50 values of vincristine were 1.2 nM when Compound I-7 was not present, 0.8 nM when Compound I-7 was present at a concentration of 2 and 0.1 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 19 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vinorelbine were 1.1 nM when Compound I-5 was not present, 0.4 nM when Compound I-5 was present at a concentration of 2 and ⁇ 0.04 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 20 .
- H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vinorelbine were 9.5 nM when Compound I-5 was not present, 5.2 nM when Compound I-5 was present at a concentration of 2 and 2.1 nM when Compound I-5 was present at a concentration of 4 ⁇ M. See FIG. 21 .
- OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-7 were 1 ⁇ M and 3 ⁇ M.
- the observed EC 50 values of vinorelbine were 2.4 nM when Compound I-7 was not present, 2.4 nM when Compound I-7 was present at a concentration of 1 and 0.1 nM when Compound I-7 was present at a concentration of 3 ⁇ M. See FIG. 22 .
- SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vinorelbine used in this assay was 40 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vinorelbine were 15.1 nM when Compound I-7 was not present, 10.1 nM when Compound I-7 was present at a concentration of 2 and 4.7 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 23 .
- A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of vinorelbine used in this assay was 50 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of vinorelbine were 27 nM when Compound I-7 was not present, 16 nM when Compound I-7 was present at a concentration of 2 and 6 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 24 .
- H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of BI2536 were 46.3 nM when Compound I-7 was not present, 17.3 nM when Compound I-7 was present at a concentration of 2 and ⁇ 0.04 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 25 .
- PANC1 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of BI2536 were 7.3 nM when Compound I-7 was not present, 4.4 nM when Compound I-7 was present at a concentration of 2 and 2.5 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 26 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of BI2536 were 6.2 nM when Compound I-7 was not present, 4.1 nM when Compound I-7 was present at a concentration of 2 and 1.7 nM when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 27 .
- A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of BI2536 were 6.2 nM when Compound I-7 was not present, 4.1 nM when Compound I-7 was present at a concentration of 3 and 1.7 nM when Compound I-7 was present at a concentration of 6 ⁇ M. See FIG. 28 .
- H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of GSK461364 used in this assay was 10 ⁇ M and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of GSK461364 were 1.9 ⁇ M when Compound I-7 was not present, 0.97 ⁇ M when Compound I-7 was present at a concentration of 2 and 0.58 ⁇ M when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 29 .
- PANC1 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of GSK461364 used in this assay was 10 ⁇ M and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of GSK461364 were 0.5 ⁇ M when Compound I-7 was not present, 0.3 ⁇ M when Compound I-7 was present at a concentration of 2 and 0.2 ⁇ M when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 30 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of GSK461364 used in this assay was 10 ⁇ M and the concentrations of Compound I-7 were 2 ⁇ M and 4 ⁇ M.
- the observed EC 50 values of GSK461364 were 0.43 ⁇ M when Compound I-7 was not present, 0.24 ⁇ M when Compound 1-7 was present at a concentration of 2 and 0.12 ⁇ M when Compound I-7 was present at a concentration of 4 ⁇ M. See FIG. 31 .
- A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2.
- the highest concentration of GSK461364 used in this assay was 1 ⁇ M and the concentrations of Compound I-7 were 3 ⁇ M and 6 ⁇ M.
- the observed EC 50 values of GSK461364 were 1.2 ⁇ M when Compound I-7 was not present, 0.5 ⁇ M when Compound I-7 was present at a concentration of 3 and 0.2 ⁇ M when Compound I-7 was present at a concentration of 6 ⁇ M. See FIG. 32 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of paclitaxel, Compound I-7, or both paclitaxel and Compound I-7 are present are shown in FIG. 33 .
- SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of paclitaxel, Compound I-7, or both paclitaxel and Compound I-7 are present are shown in FIG. 34 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of vincristine, Compound I-7, or both vincristine and Compound I-7 are present are shown in FIG. 35 .
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of vinorelbine, Compound I-7, or both vinorelbine and Compound I-7 are present are shown in FIG. 36 .
- SW620 cells were cultured and treated as described in Example 1.
- PI propidium iodide
- manufacturer's protocol supplied with the Guava Cell Cycle Reagent for Flow Cytometry (EMD Millipore) was followed.
- the measurements were performed with Guava PCA-96 flow cytometer (EMD Millipore) using the green laser for excitation at 535 nm and monitoring emission at 617 nm.
- SW620 cells were cultured, treated, and analyzed as described in Examples 1.
- PI propidium iodide
- manufacturer's protocol supplied with the Guava Cell Cycle Reagent for Flow Cytometry (EMD Millipore) was followed.
- the measurements were performed with Guava PCA-96 flow cytometer (EMD Millipore) using the green laser for excitation at 535 nm and monitoring emission at 617 nm.
- SW620 cells were incubated for 24 hours in FBS ⁇ media, which contained different concentrations of either AZ191 or Compound I-7.
- exposure to AZ191 led to no decrease in fraction of cells in quiescent state (G 0 ) based on no observed change in the fraction of cells G 0 +G 1 phase.
- exposure to same or lower concentrations of Compound I-7 led to a significant decrease in fraction of cells in quiescent state (G 0 ) based on the significant decrease in the fraction of cells G 0 +G 1 phase.
- AZ191 inhibits DYRK1B at 17 nM (Ashford A L, Oxley D, Kettle J, Hudson K, Guichard S, Cook S J, Lochhead P A (2014) A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochemical Journal 457, 43-56).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
Description
- This application is a divisional of U.S. patent application Ser. No. 15/488,143, filed Apr. 14, 2017, which itself claims the benefit of U.S. Provisional Patent Application No. 62/323,583, filed Apr. 15, 2016, each of which is incorporated by reference herein in its entirety.
- Cancer cell quiescence, effectively a cell in a state of sleep, has been recognized recently as a major mechanism of the resistance of cancer cells to treatments and for providing a pathway for disease recurrence. This quiescence, alternatively called cellular dormancy, is due to arrest at G0 phase of the cell cycle. Typically, a cell enters a cell cycle from gap phase 1 (G1), as shown in
FIG. 1 . After a synthesis phase (S) and a short pre-mitotic interval (G2), the cell divides by mitosis (M) followed by a return to G1. Instead of G1 however, a cell can enter cellular dormancy or quiescence, designated as the G0 phase. Cancer cells can either enter an irreversible state before undergoing terminal differentiation, termed senescence, or enter a reversible, true quiescent G0 state from which they could resume cycling, like quiescent fibroblasts (Coller H A, Sang L, and Roberts J M (2006) A new description of cellular quiescence, PLoS Biology 4, e83). - A population of cells naturally may be in a quiescent state at any given time and remain quiescent for an indeterminate period until receipt of a signal to enter the cell division cycle. In one example, the proportion of cancer cells in quiescent state within a population in a tumor may be increased by environmental factors, such as lack of nutrients, hypoxia, high concentration of reactive oxygen species, etc. Cells may also be induced into the quiescent state by the action of a drug substance, as in pharmacological quiescence.
- The energy and nutrient requirements of a quiescent cell are reduced relative to a dividing cell. Since current cancer therapies target dividing cells, as illustrated in
FIG. 2 , and therefore a cancer cell must be in the cell division cycle for such treatments to affect it. Accordingly, a quiescent cancer cell is resistant to treatments that affect one of more cellular proliferation processes by means of damaging exposed DNA, interfering with DNA replication or repair, interfering with mitosis, or other mechanisms. - Both anticancer therapeutics and radiation treatments produce adverse effects. Consequently, doses and duration of treatment are limited by toxicity and lower effective doses and/or shorter treatment durations are highly desirable. Upon reduction in doses or discontinuation of treatment, however, the surviving quiescent cancer cells can cause cancer recurrence upon re-entry to the cell cycle, the timing of which cannot be predicted. Further, metastatic cancer cells in the bloodstream may experience a period of quiescence while they adapt to their new microenvironment (Chaffer C L and Weinberg R A (2011) A perspective on cancer cell metastasis, Science 331, 1559-1564). Quiescent cancer cells degrade their polyribosomes, thus blocking translation and reducing total RNA and protein content. These shrunk cancer cells may be able to enter the bores of capillaries (approximately 8 μm diameter) whereas cycling cancer cells are usually much larger (20-30 μm).
- Accordingly, the existence of a population of quiescent cancer cells within a neoplasm is recognized as an obstacle to successful and durable treatment (Jackson R C (1989) The problem of the quiescent cancer cell, Advances in Enzyme Regulation 29, 27-46). Evidence for resistance of quiescent cancer cells derived from various cancer types and to various anti-cancer treatments has been reported.
- Yet, despite a growing appreciation of the importance of cancer cell quiescence, this issue remains unaddressed clinically. Accordingly, the present invention provides methods and combinations for the treatment of neoplasms that features the targeting of quiescent cancers cells by small molecules, particularly molecules effective against quiescent cancer cells, in combination with treatments known to be effective against certain neoplastic cells.
- The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor).
- Generally, the invention features a method of treating a neoplasm comprising: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent effective against quiescent cancer cells; and (b) second agent which is an inhibitor of mitosis, wherein the two agents can be administered sequentially or concomitantly. In some embodiments, the neoplasm is a cancer or a population of cancer cells in vitro or in vivo. In some embodiments, the subject receiving the treatment is diagnosed with cancer (e.g., metastatic or pre-metastatic). In some embodiments, the subject has been previously treated with a first-line therapy against cancer. In some embodiments, the subject is treated, or has been treated, with two or more inhibitors of mitosis sequentially or concomitantly.
- In some embodiments, the combined treatment may result in improved outcomes, such as increased survival, reduction of severity, delay or elimination of recurrence, or reduced side effects of the primary treatments (i.e., the inhibitor of mitosis). In some embodiments, the second agent is administered at lower dose and/or for a shorter duration when administered as part of the combination as compared to a treatment with the agent alone. For example, in some embodiments, the EC50 value of the inhibitor of mitosis is at least 20% lower in the combination treatment when compared to the same treatment with the inhibitor of mitosis alone, as determined, for example, in cell-based assays. In some embodiments, the combination treatment increases fraction of apoptotic cells in a treated population as compared to either agent alone, by at least by 2-fold as determined, for example, by fraction of sub-G0 cells by FACS assay.
- In one embodiment, the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor. In some embodiments, the DYRK1 inhibitor is a compound that inhibits activity of a DYRK1 kinase, either DYRK1A or DYRK1B (in vitro or in vivo), for example, with an IC50 of 100 nM or lower in biochemical assays. In some embodiments, the DYRK1 inhibitor reduces the fraction of quiescent cancer cells (in vitro or in vivo) that would otherwise be found in the absence of such inhibitor, for example, by at least 10%. In some embodiments, the DYRK1 inhibitor inhibits both DYRK1A and DYRK1B. In some embodiments, the DYRK1 inhibitor is selective for DYRK1A or DYRK1B.
- In one embodiment, the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor. In one embodiment, the DYRK1 inhibitor is a compound of formula I:
- or a pharmaceutically acceptable salt or solvate thereof, wherein,
R1 is a substituted or unsubstituted C1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl;
R2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO2, NHC(O)C1-4 alkyl, C1-4 alkyl, OH, OC1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S. - In one embodiment, the compound of formula I is selected from:
- In another embodiment, the methods of the invention further provide (c) administering to the subject another cancer therapy, for example, radiation therapy or other cancer treatment.
- In one embodiment, the methods of the invention comprise: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent of formula I; (b) an inhibitor of mitosis; and (c) radiation therapy; each therapy being administered sequentially or concomitantly. For example, in some embodiments, the subject is first treated with radiation therapy, whereupon the subject is administered a therapeutic agent of Formula I, alone or in combination with the inhibitor of mitosis. In some embodiments, the subject is co-administered (a) the therapeutic agent effective against quiescent cancer cells, (b) the inhibitor of mitosis and, optionally, (c) the radiation therapy. In some embodiments, the inhibitor of mitosis is an inhibitor of mitosis effective to treat or prevent a neoplasm, including but not limited to, all such compounds approved for the treatment of cancer and compounds that otherwise demonstrate efficacy in treating cancer in mammalian subject (e.g., mice, rats, dogs, monkeys, humans), and compounds that demonstrate efficacy against neoplastic cells in vitro. Many such compounds are known.
- In one embodiment, the inhibitor of mitosis is a taxane. In a further embodiment, the taxane inhibitor of mitosis is, for example, BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
- In another embodiment, the inhibitor of mitosis is a vinca alkaloid. In a further embodiment, the vinca alkaloid inhibitor of mitosis is, for example, vinblastine, vincristine, vindesine, vinflunine, and vinorelbine. In another embodiment, the vinca alkaloid inhibitor of mitosis is vintafolide.
- In another embodiment, the inhibitor of mitosis is a PLK1 inhibitor. In a further embodiment, the PLK1 inhibitor of mitosis is, for example, BI-2536, GSK 461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib. In a further embodiment, the inhibitor of mitosis is BI-2536 or GSK461364.
- In another embodiment, the neoplasm being treated is a cancer, for example, biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer (e.g. melanoma), testicular cancer, thyroid cancer, or uterine cancer. In a further embodiment, the neoplasm being treated is a bladder cancer, breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, and prostate cancer. In further embodiments, the cancer is primary or metastatic. In yet further embodiments, the cancer is of the type represented by the cell line types shown in the Examples.
- The embodiments are not meant to be limiting with regard to additional combination components, especially therapeutic agents and inhibitors that are part of existing treatment combinations, such as, for example, TPF wherein T stands for Taxotere®, that is docetaxel, or PCV wherein V stands for vincristine sulfate. Similarly, the embodiments are not meant to be limiting with regard to routes and order of administration or with regard to patient type (previously untreated or previously treated, absence or presence of co-morbid conditions, sex, etc.) or stage of patient's disease, type of inhibitor of mitosis, etc.
-
FIG. 1 shows a schematic diagram of a mitotic cycle of a eukaryotic cell. -
FIG. 2 shows a schematic diagram of a mitotic cycle of a eukaryotic cancer cell annotated to indicate the stages of the cell cycle upon which some of the available anti-cancer therapeutic agents are believed act. -
FIG. 3 shows effect of combination of paclitaxel and Compound I-5 (0, 2, and 4 μM) on the growth of SW620 cells. -
FIG. 4 shows effect of combination of paclitaxel and Compound I-7 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 5 shows effect of combination of paclitaxel and Compound I-5 (0, 2, and 4 μM) on the growth of LNCap cells. -
FIG. 6 shows effect of combination of paclitaxel and Compound I-7 (0, 3, and 6 μM) on the growth of HCC827 cells. -
FIG. 7 shows effect of combination of paclitaxel and Compound I-7 (0, 3, and 6 μM) on the growth of A549 cells. -
FIG. 8 shows effect of combination of paclitaxel and Compound I-7 (0, 2, 4, 8, and 10 μM) on the growth of SK-OV-3 cells. -
FIG. 9 shows effect of combination of paclitaxel and Compound I-7 (0, 2, and 4 μM) on the growth of OVCAR3 cells. -
FIG. 10 shows effect of combination of docetaxel and Compound I-5 (0, 2, and 4 μM) on the growth of SW620 cells. -
FIG. 11 shows effect of combination of docetaxel and Compound I-7 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 12 shows effect of combination of docetaxel and Compound I-7 (0, 3, and 6 μM) on the growth of HCC827 cells. -
FIG. 13 shows effect of combination of docetaxel and Compound I-7 (0, 3, and 6 μM) on the growth of A549 cells. -
FIG. 14 shows effect of combination of docetaxel and Compound I-7 (0, 4, and 8 μM) on the growth of SK-OV-3 cells. -
FIG. 15 shows effect of combination of docetaxel and Compound I-7 (0, 2, and 4 μM) on the growth of OVCAR3 cells. -
FIG. 16 effect of combination of vincristine and Compound I-5 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 17 shows effect of combination of vincristine and Compound I-5 (0, 2, and 4 μM) on the growth of H1975 cells. -
FIG. 18 shows effect of combination of vincristine and Compound I-7 (0, 4, and 8 μM) on the growth of SK-OV-3 cells. -
FIG. 19 shows effect of combination of vincristine and Compound I-7 (0, 1, and 3 μM) on the growth of OVCAR3 cells. -
FIG. 20 shows effect of combination of vinorelbine and Compound I-5 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 21 shows effect of combination of vinorelbine and Compound I-5 (0, 2, and 4 μM) on the growth of H1975 cells. -
FIG. 22 shows effect of combination of vinorelbine and Compound I-7 (0, 1, and 3 μM) on the growth of OVCAR3 cells. -
FIG. 23 shows effect of combination of vincristine and Compound I-7 (0, 4, and 8 μM) on the growth of SK-OV-3 cells. -
FIG. 24 shows effect of combination of vincristine and Compound I-7 (0, 3, and 6 μM) on the growth of A549 cells. -
FIG. 25 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 μM) on the growth of H1975 cells. -
FIG. 26 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 μM) on the growth of PANC1 cells. -
FIG. 27 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 28 shows effect of combination of B12536 and Compound I-7 (0, 2, and 4 μM) on the growth of A549 cells. -
FIG. 29 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 μM) on the growth of H1975 cells. -
FIG. 30 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 μM) on the growth of PANC1 cells. -
FIG. 31 shows effect of combination of GSK461364 and Compound I-7 (0, 2, and 4 μM) on the growth of DMS273 cells. -
FIG. 32 shows effect of combination of GSK461364 and Compound I-7 (0, 3, and 6 μM) on the growth of A549 cells. -
FIG. 33 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS− media; Panel C: FBS+ media with 4 μM Compound I-7; Panel D: FBS+ media with 2.7 nM paclitaxel; Panel E: FBS+ media with 5 μM Compound I-7 and 2 nM paclitaxel. -
FIG. 34 shows FACS analyses of cell cycle distribution of SW620 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS− media; Panel C: FBS+ media with 4 μM Compound I-7; Panel D: FBS+ media with 2 nM paclitaxel; Panel E: FBS+ media with 4 μM Compound I-7 and 2 nM paclitaxel. -
FIG. 35 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS− media; Panel C: FBS+ media with 4 μM Compound I-7; Panel D: FBS+ media with 1.1 nM vincristine; Panel E: FBS+ media with 4 μM Compound I-7 and 1.1 nM vincristine. -
FIG. 36 shows FACS analyses of cell cycle distribution of DMS273 cells incubated for 24 hours in Panel A: FBS+ media; Panel B: FBS− media; Panel C: FBS+ media with 4 μM Compound I-7; Panel D: FBS+ media with 8.1 nM vinorelbine; Panel E: FBS+ media with 4 μM Compound I-7 and 8.1 nM vinorelbine. -
FIG. 37 FACS analyses by DNA content of cell cycle distribution of SW620 cells. The cells were incubated in Panel A: 24 hours in FBS− media; Panel B: 24 hours in FBS− media with 2.5 μM AZ191; Panel C: 24 hours in FBS− media with 5 μM AZ191; Panel D: 24 hours in FBS− media with 10 μM AZ191. -
FIG. 38 shows FACS analyses by DNA content of cell cycle distribution of SW620 cells. The cells were incubated in Panel A: 24 hours in FBS− media with DMSO control; Panel B: 24 hours in FBS− media with 1.25 μM Compound I-7; Panel C: 24 hours in FBS− media 2.5 μM Compound I-7; Panel D: 24 hours in FBS− media with 5 μM Compound I-7. - In the present invention, an “alkyl” group is a saturated, straight or branched, hydrocarbon group, comprising from 1 to 8 carbon atoms (C1-8 alkyl group), in particular from 1 to 6, or from 1 to 4 carbons atoms, unless otherwise indicated. Examples of alkyl groups having from 1 to 6 carbon atoms inclusive are methyl, ethyl, propyl (e.g., n-propyl, iso-propyl), butyl (e.g., tert-butyl, sec-butyl, n-butyl), pentyl (e.g., neo-pentyl), hexyl (e.g., n-hexyl), 2-methylbutyl, 2-methylpentyl and the other isomeric forms thereof. Alkyl groups may be unsubstituted or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- In the present invention, an “alkenyl” group is a straight or branched hydrocarbon group comprising at least one double carbon-carbon bond, comprising from 2 to 8 carbon atoms (unless otherwise indicated). Examples of alkenyl groups containing from 2 to 6 carbon atoms are vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl and the isomeric forms thereof. Alkenyl groups may be unsubstituted, or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- In the present invention, an “alkynyl” group is a straight or branched hydrocarbon group comprising at least one triple carbon-carbon bond, comprising from 2 to 8 carbon atoms. Alkynyl groups may be substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups.
- In the present invention, an “aryl” group is an aromatic hydrocarbon cycle, comprising from 5 to 14 carbon atoms. Most preferred aryl groups are mono- or bi-cyclic and comprises from 6 to 14 carbon atoms, such as phenyl, alpha-naphtyl, 3-naphtyl, antracenyl, preferably phenyl. “Aryl” groups also include bicycles or tricycles comprising an aryl cycle fused to at least another aryl, heteroaryl, cycloalkyl or heterocycloalkyl group, such as benzodioxolane, benzodioxane, dihydrobenzofurane or benzimidazole. Aryl groups may be unsubstituted, or substituted by at least one (e.g. 1, 2 or 3) group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups. In addition, aryl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- In the present invention, a “halogen atom” or “halo” is a Cl, Br, F, or I atom.
- In the present invention, an “alkoxyl” group is an alkyl group linked to the rest of the molecule through an oxygen atom, of the formula O-alkyl.
- In the present invention, an “amino” group is a NH2, NH-alkyl, or N(alkyl)2 group.
- In the present invention, a “heteroaryl” group is an aryl group whose cycle is interrupted by at least at least one heteroatom, for example a N, O, or S, atom, such as thiophene or pyridine. Heteroaryl groups may be unsubstituted, or substituted by at least one (e.g. 1, 2 or 3) group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro and amino groups. In addition, heteroaryl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- In the present invention, a “cycloalkyl” denotes a saturated alkyl group that forms one cycle having preferably from 3 to 14 carbon atoms, and more preferably 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Cycloalkyl groups may be unsubstituted or substituted by at least one (e.g. 1, 2 or 3) group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro, and amino groups. In addition, cycloalkyl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- In the present invention, a “heterocycloalkyl” group is a cycloalkyl group comprising at least one heteroatom, such as pyrrolidine, tetrahydrothiophene, tetrahydrofuran, piperidine, pyran, dioxin, morpholine or piperazine. A heterocycloalkyl group may in particular comprise from four to fourteen carbon atoms, such as morpholinyl, piperidinyl, pyrrolidinyl, tetrahydropyranyl, dithiolanyl. Heterocycloalkyl groups may be unsubstituted, or substituted by at least one group chosen from halogen atoms, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxyl, alkoxyl, alkenyl, alkynyl, CN, nitro and amino groups. In addition, heterocycloalkyl groups may be substituted by adjacent substituents which can, taken together with the carbon atom to which they are attached, form a 5- to 6-membered ring which may contain one or more heteroatom(s) selected from N, O, and S.
- As used herein, a “neoplasm” means an abnormal mass of tissue that results from neoplasia. “Neoplasia” means a process of an abnormal proliferation of cells. In some embodiments of the invention, a neoplasm is a solid cancer, or alternately a hematopoietic cancer. The neoplasia may be benign, pre-malignant, or malignant. The term neoplasm encompasses mammalian cancers, in some embodiments, human cancers, and carcinomas, sarcomas, blastomas of any tissue (for example adenocarcinomas, squamous cell carcinoma, osteosarcomas, etc.), germ cell tumors, glial cell tumors, lymphomas, leukemias, including solid and lymphoid cancers, kidney, breast, lung, bladder, colon, ovarian, prostate, rectal, pancreatic, stomach, brain, head and neck, skin, uterine, cervical, testicular, esophagus, thyroid, biliary cancer, liver cancer, and cancer of the bone and cartilaginous tissue, including non-Hodgkin's lymphomas (e.g., Burkitt's, Small Cell, and Large Cell lymphomas) and Hodgkin's lymphoma, leukemia, multiple myeloma, and myelodysplastic syndrome.
- As used herein, the terms “treat,” “treating,” or “treatment,” mean to counteract a medical condition (e.g., cancer) to the extent that the medical condition is improved according to a clinically-acceptable standard. Improvement in cancer can include: 1) reduced rate of tumor growth (tumor growth inhibition), 2) tumor shrinkage (regression), 3) remission, whether partial or total, 4) reduction in metastases, 5) prolonging progression free survival, and 6) delay or elimination of recurrence. In certain embodiments of the invention, treating includes achieving, partially or substantially, one or more of the following results: partially or totally reducing the cancer mass, or volume, or the malignant cell count; ameliorating or improving a clinical symptom or indicator associated with solid cancers or hematopoietic cancers; delaying, inhibiting, or preventing the progression of solid cancers or hematopoietic cancers; or partially or totally delaying, inhibiting or preventing the onset or development of solid cancers or hematopoietic cancers. “Treatment” also can mean prolonging survival compared to expected survival without treatment or compared to standard of care treatment.
- Treating includes prophylactic or preventative treatment. “Prophylactic treatment” refers to treatment before appearance or re-appearance of clinical symptoms of a target disorder to prevent, inhibit, or reduce its occurrence, severity, or progression.
- As used herein, an “effective amount” refers to an amount of a therapeutic agent or a combination of therapeutic agents that is therapeutically or prophylactically sufficient to affect the desired improvement in the targeted disorder. Examples of effective amounts typically range from about 0.0001 mg/kg of body weight to about 500 mg/kg of body weight per single administered dose, such doses being administered once or over a period of time. An example range is from about 0.0001 mg/kg of body weight to about 5 mg/kg per dose. In other examples, the range can be from about 0.0001 mg/kg to about 5 mg/kg per single administered dose. In still other examples, effective amounts range from about 0.01 mg/kg of body weight to 50 mg/kg of body weight per single administered dose, or from 0.01 mg/kg of body weight to 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 10 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, or 40 mg/kg of body weight per single administered dose. For agents of known clinical use, an example of an effective dose is that amount approved of by a regulatory agency for treatment of an indication.
- As used herein, the term “subject” refers to a mammal, for example a human, but can also mean an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like), and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
- As used herein, the term “therapeutic agent” means any chemical molecule used or contemplated for use or investigated for use in cancer treatment, including cytotoxic, cytostatic, or targeted agents, whether small molecules, or peptides, or antibodies, or oligonucleotides, irrespective of mechanism of action. As used herein, the terms “therapeutic” or “therapeutic agent” refer to either the active pharmaceutical ingredient (API) or its pharmaceutically acceptable salt or hydrate (solvate), or a drug product containing the therapeutic agent, however formulated, and whether API is amorphous or crystalline and of whatever polymorphic form. Formulation means a combination of an active pharmaceutical ingredient (API, drug substance) or ingredients (APIs) combined with excipients and/or delivery vehicle to make an administrable dosage form (drug product). For example, as used herein, a reference to paclitaxel includes Taxol®, Abraxane®, Lipusu®, and any other drug product with paclitaxel as the active ingredient.
- The therapeutic agents of the invention can be administered alone, but are generally administered with a pharmaceutically acceptable carrier, with respect to standard pharmaceutical practice (such as described in Remington's Pharmaceutical Sciences, Mack Publishing). Accordingly, a further object of this invention relates to pharmaceutical compositions defined herein and pharmaceutically acceptable carriers.
- As used herein, the term “inhibitor” means any composition that reduces the activity of an enzyme. An example of an inhibitor is a chemical molecule. A measure of the potency of an inhibitor is its “50% inhibitory concentration” (IC50). IC50 concentration or IC50 value is the concentration of an inhibitor at which 50% of the enzymatic activity is inhibited by the inhibitor. Methods for the determination of IC50 values, for example, of kinase inhibitors are known to persons of ordinary skill in the art and include direct and indirect functional assays, such as the HotSpot™ kinase assay technology (Reaction Biology Corporation, Malvern, Pa., www.reactionbiology.com) or competition binding assays, such as KINOMEscan® (DiscoverX Corporation, Freemont, Calif., www.discoverx.com).
- A measure of the potency of a therapeutic agent against a cell line is its “50% effective concentration” (EC50). EC50 concentration or EC50 value is the concentration of a drug that produces half-maximal response, such as, for example, 50% growth inhibition or 50% reduction in cell viability. Methods for the determination of EC50 values, for example, of kinase inhibitors are known to persons of ordinary skill in the art.
- As used herein, the term “quiescence” or “quiescent state” refers to the G0 state of the cell cycle, as understood by the practitioners of the art.
- As used herein, the term “therapeutic agent effective against quiescent cancer cells” refers to a molecule that either reduces the fraction of quiescent cancer cells in a cell population or prevents, completely or substantially, an increase in fraction of quiescent cancer cells in a cell population under conditions that otherwise would lead to such an increase.
- A “quiescent neoplastic cell”, alternately referred to as a “quiescent cancer cell” means a cancer cell that exists in the quiescent, or G0, state of the cell cycle. A “fraction of quiescent neoplastic cells” or “fraction of quiescent cancer cells”, as used herein, means the portion of a cancer cell population that exists in the G0 state of the cell cycle. Determining the fraction of quiescent neoplastic cells includes characterizing a cell population by distribution of its constituent cells within the stages of the cell cycle. The fraction of cells in the G0 state (i.e., quiescent neoplastic cells) is quantified relative to the total cell population. The fraction may be expressed as a percentage of the total cell population (i.e. (number of quiescent cells divided by total cells in cell population) multiplied by 100). Characterization of the cell population by distribution of its constituent cells within the stages of the cell cycle may be achieved by techniques known to persons of ordinary skill in the art, and may include analysis by DNA and/or RNA content using flow cytometry methods, for example, fluorescence-activated cell sorting (FACS).
- The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancers cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents which are inhibitors of mitosis.
- Generally, the invention features a method of treating a neoplasm comprising: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent effective against quiescent cancer cells; and (b) second agent which is an inhibitor of mitosis, wherein the two agents can be administered sequentially or concomitantly. In some embodiments, the neoplasm is a cancer or a population of cancer cells in vitro or in vivo. In some embodiments, the subject receiving the treatment is diagnosed with cancer (e.g., metastatic or pre-metastatic). In some embodiments, the subject has been treated previously with a first-line therapy against cancer. In some embodiments, the subject has been treated previously with second-line and/or other therapies. In some embodiments, the subject is treated, or has been treated, with radiation therapy. In some embodiments, the subject was treated with surgery, for example to resect or de-bulk a tumor. In other embodiments, the subject's neoplasm has recurred. In some embodiments, the subject is treated, or has been treated, with two or more inhibitor of mitosis sequentially or concomitantly.
- In some embodiments, the combined treatment may result in improved outcomes, such as increased survival, reduction of severity, delay or elimination of recurrence, or reduced side effects of the primary treatments (i.e., the inhibitor of mitosis). In some embodiments, the second agent is administered at lower dose and/or for a shorter duration when administered as part of the combination as compared to a treatment with the agent alone. For example, in some embodiments, the EC50 value of the inhibitor of mitosis is at least 20%, 25%, 30%, 40%, 50%, 100%, 3-fold, 5-fold, 10-fold lower in the combination treatment when compared to the same treatment with the first agent, as determined, for example, in cell-based assays. In some embodiments, the combination treatment increases fraction of apoptotic cells in a treated population as compared to either agent alone, by at least by 2-fold, 3-fold, 4-fold, 5-fold as determined, for example, by fraction of sub-G0 phase cells in a FACS assay.
- In one embodiment, the therapeutic agent effective against quiescent cancer cells is a DYRK1 inhibitor. In some embodiments, the DYRK1 inhibitor is a compound that inhibits activity of a DYRK1 kinase, either DYRK1A or DYRK1B (in vitro or in vivo), for example, with an IC50 value of <100 nM, <90 nM, <80 nM, <70 nM, <60 nM, <50 nM, <40 nM, <30 nM, <20 nM, <10 nM, <5 nM or lower in biochemical assays. In some embodiments, the DYRK1 inhibitor reduces the fraction of quiescent cancer cells (in vitro or in vivo) in a population or a tumor that would otherwise be found in the absence of such inhibitor, for example, by at least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or more.
- In some embodiments, the DYRK1 inhibitor inhibits both DYRK1A and DYRK1B. In some embodiments, the DYRK1 inhibitor is selective for DYRK1A, with ratio of DYRK1B IC50 to DYRK1A IC50 of 1000, 100, 50, 25, 10 to 1. In some embodiments, the DYRK1 inhibitor is selective for DYRK1B, with ratio of DYRK1A IC50 to DYRK1B IC50 of 1000, 100, 50, 25, 10, or 5 to 1. In some embodiments, the DYRK1 inhibitor is selective for DYRK1 by at least 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold as compared to DYRK2 and/or DYRK3 and/or DYRK4, as determined by ratios of IC50 values. In some embodiments, the DYRK1 inhibitor is selective for DYRK1 by at least 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 500-fold, 1000-fold as compared to cyclin dependent kinases (CDKs) such, as for example, CDK2, as determined by ratios of IC50 values.
- Examples of known DYRK1 inhibitors include AZ191, DYRKi, harmine, ID-8, leucettine L41, NCGC00185981, INDY, ProINDY, TC-S 7004, and TG003. At least one known DYRK1 inhibitor, TC-S 7004, (US20120184562) is reported to be effective against quiescent cancer cells in vitro (Ewton D Z, Hu J, Vilenchik M, Deng X, Luk K C, Polonskaia A, Hoffman A F, Zipf K, Boylan J F, and Friedman E A. (2011) Inactivation of MIRK/DYRK1B kinase targets quiescent pancreatic cancer cells. Molecular Cancer Therapeutics 10: 2104-2114).
- In one embodiment, the DYRK1 inhibitor is a compound of formula I:
- or a pharmaceutically acceptable salt or solvate thereof, wherein,
R1 is a substituted or unsubstituted C1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl;
R2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO2, NHC(O)C1-4 alkyl, C1-4 alkyl, OH, OC1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S. - In one embodiment, the compound of formula I is selected from:
- In another embodiment, the methods of the invention further provide (c) administering to the subject another cancer therapy, for example, radiation therapy or other cancer treatment.
- In one embodiment, the methods of the invention comprise: administering to a subject in need thereof a therapeutically effective amount of (a) a therapeutic agent of formula I; (b) an inhibitor of mitosis; and (c) radiation therapy; each therapy being administered sequentially or concomitantly. For example, in some embodiments, the subject is first treated with radiation therapy, whereupon the subject is administered a therapeutic agent of Formula I, alone or in combination with the inhibitor of mitosis. In some embodiments, the subject is co-administered (a) the therapeutic agent effective against quiescent cancer cells, (b) the inhibitor of mitosis, and, optionally (c) the radiation therapy.
- In some embodiments, the inhibitor of mitosis is an inhibitor of mitosis effective to treat or prevent a neoplasm, including but not limited to, all such compounds approved for the treatment of cancer, compounds in clinical trials for the treatment of cancer, compounds that otherwise demonstrate efficacy in treating cancer in mammalian subject (e.g., mouse, rats, monkeys, humans), and compounds that demonstrate efficacy against neoplastic cells in vitro. Many such compounds are known.
- In one embodiment, the inhibitor of mitosis is a taxane. Taxanes useful for the methods of the invention include BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
- In another embodiment, the inhibitor of mitosis is a vinca alkaloid. Vinca alkaloids useful for the methods of the invention include vinblastine, vincristine, vindesine, vinflunine, and vinorelbine. In another embodiment, the vinca alkaloid inhibitor of mitosis is vintafolide.
- In another embodiment, the inhibitor of mitosis is a PLK1 inhibitor. PLK1 inhibitors useful for the methods of the invention include BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib. In a further embodiment, the inhibitor of mitosis is BI-2536 or GSK461364.
- In another embodiment, a neoplasm is biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer (e.g. melanoma), testicular cancer, thyroid cancer, or uterine cancer. In a further embodiment, the neoplasm is selected from bladder cancer, breast cancer, colorectal cancer, non-small cell lung cancer, small cell lung cancer, ovarian cancer, and prostate cancer. In further embodiments, the cancer is primary or metastatic. In yet further embodiments, the cancer is of the type represented by the cell line types shown in the Examples.
- The embodiments are not meant to be limiting with regard to additional combination components, especially compounds that are part of existing treatment combinations, such as, for example, TPF wherein T stands for Taxotere®, that is docetaxel, or PCV wherein V stands for vincristine sulfate. The embodiments described here are illustrative and are not meant to be limiting with regard to routes and order of administration, patient type (previously untreated or previously treated, absence or presence of co-morbid conditions, age, sex, etc.), or stage of patient's disease, type of inhibitor of mitosis, etc.
- Inhibitors of mitosis are known in the art (Dominguez-Brauer C, et al, (2015) Targeting mitosis in cancer: emerging strategies,
Molecular Cell 60, 524-536). As used herein, the terms “inhibitor of mitosis” and “mitotic inhibitor” are equivalent and may be used interchangeably. An inhibitor of mitosis interrupts cell cycling during the M phase or at a checkpoint entering (the G2/M checkpoint) or leaving (the post-mitotic checkpoint) the M phase. In M phase, the chromosomes and cytoplasm are divided into two daughter cells (cytokinesis). Mitosis proceeds in five phases: prophase, prometaphase, metaphase, anaphase, and telophase and an inhibitor of mitosis can interrupt any of these phases. Examples inhibitors of mitosis include taxanes, vinca alkaloids, and PLK1 inhibitors. - For example, taxanes include BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927); vinca alkaloids include vincristine, vinblastine, vindesine, vinflunine, and vinorelbine; PLK1 inhibitors include BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
- A G0 state is maintained by a specific program of gene expression. DYRK1 kinases, such as DYRK1A and DYRK1B, may be important for the maintenance of cancer cells in G0 state (quiescent state).
- DYRK1B/Mirk is a member of the Minibrain/DYRK family of kinases which mediates survival and differentiation in certain normal tissues. (Kentrup H, Becker W, Heukelbach J, Wilmes A, Schurmann A, Huppertz C, Kainulainen H, and Joost H G (1996) Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII, Journal of Biological Chemistry 271, 3488-3495; Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor F J, and Joost H G (1998) Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases, Journal of Biological Chemistry 273, 25893-25902). DYRK1B is expressed at detectable levels in skeletal muscle cells and testes. Knockout of DYRK1B caused no evident abnormal phenotype in mice even in developing muscle, suggesting that DYRK1B is not an essential gene for normal development. Supporting this interpretation, normal fibroblasts exhibited no alteration in survival after 20-fold depletion of DYRK1B kinase levels. Thus, DYRK1B does not appear to be an essential gene for survival of normal cells yet there is evidence that it is upregulated in certain malignant cancer cells in which DYRK1B is believed to mediate survival by retaining cancer cells in quiescent state. These unusual characteristics suggest that DYRK1B may be an attractive target for therapeutic intervention and in particular for anti-cancer therapy directly against quiescent cancer cells.
- The disclosed combinations and methods may afford one or more of the improvements as defined in the Glossary relative to the use of each individual components or existing single and combination treatments. Also, the disclosed combinations and methods may permit reduction in doses and/or frequency of administration of therapeutic agents and radiation to achieve the same improvements as a result of treatment relative to what is possible using individual components or existing single and combination treatments.
- The disclosed combinations need not be synergistic to yield a significant improvement in the effectiveness of treatment relative to single therapy with an inhibitor of mitosis. As discussed above, quiescent cancer cells are inherently less susceptible to anti-cancer therapeutics, including mitotic inhibitors, and even a small fraction of quiescent cells that survives post treatment can lead to recurrence. Consequently, eradicating the resistant, quiescent cell populations in a neoplasm may or may not yield a synergistic reduction in EC50 values yet may yield a significant improvement in cancer recurrence and appearance of metastatic neoplasms.
- The administration regimen and routes of administration of the disclosed combinations may well vary depending on the neoplasm treated, extent of progression of the neoplasm, exact combination selected, age, sex, and physical condition of the subject, and other factors. Administration regimen may include multiple doses per period of time, the treatments administered concurrently or sequentially, etc. Furthermore, the combinations may be administered to subjects who are naive to treatment (have not been treated), or subjects who underwent previous treatments, or have undergone surgical resection or debulking of a solid tumor, or subjects whose cancers relapsed. For example, therapeutic agent effective against quiescent cancer cells may be administered before the inhibitor of mitosis. The therapeutic agent effective against quiescent cancer cells may be administered 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, one week before the inhibitor of mitosis. The therapeutic agent effective against quiescent cancer cells may be administered at the same time (concomitantly) as the inhibitor of mitosis. The therapeutic agent effective against quiescent cancer cells may be administered 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours after the inhibitor of mitosis. The therapeutic agent effective against quiescent cancer cells and/or the inhibitor of mitosis may be administered before, after, or concomitantly with radiation or other therapy.
- The therapeutic agent effective against quiescent cancer cells may be administered daily, every two days, every three days, every four days, once weekly, once every two weeks, once per month by oral, intravenous (IV), intraperitoneal (IP), subcutaneous (SC), intratumoral (IT), intrathecal, or other routes of administration.
- The combinations may be administered to subjects who are naive to treatment (have not been treated), or subjects who underwent previous treatments with first-line, second-line, third-line, or other therapies, radiation treatments, or have undergone surgical resection or debulking of a solid tumor, or subjects whose cancers relapsed, or subjects whose cancers are non-metastatic or metastatic.
- The following examples are not intended to be limiting. Those of skill in the art will, in light of the present disclosure, appreciate that many changes can be made in the specific materials and which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
- The following cell lines were obtained from ATCC and cultured according to the ATCC recommendations: DMS273—small cell lung cancer cell line; H1975—non-small cell lung cancer cell line harboring L858R and T790M mutations in EGFR TK; A549—a non-small cell lung cancer cell line with wild type EGFR; LNCap—prostate cancer cell line; SW620—colon cancer cell line; MiaPaCa2—pancreatic cancer cell line; PANC1—pancreatic cancer cell line; OVCAR3—ovarian cancer cell line; SK-OV-3—ovarian cancer cell line.
- Cell cultures were seeded into 6-well plates at 3×105-6×105 cells/well; the plated number of cells depended on cell size and rate of proliferation, aiming for approximately 50% confluency. After seeding, the cells were allowed to attach for 24 hours while incubated at 37° C. in a humidified 5% CO2 atmosphere, and then treated with compounds for desired amount of time (usually 24 hours) incubating under same conditions. Then the cells were harvested by trypsinization, pooled with the floating cells, washed in PBS, and fixed in 70% ice-cold ethanol overnight. For Acridine Orange (AO) staining, fixed cells were washed once with ice-cold PBS, re-suspended in 100 μL PBS, followed by addition of 200 μL of permeabilizing solution and 600 μL AO staining solution. The measurements were performed with Guava easyCyte HT flow cytometer (EMD Millipore) using the blue laser for excitation at 488 nm, monitoring emission of the AO-DNA complex at 526 nm and AO-RNA complex at 650 nm. The complete protocol and composition of buffers are described in the literature (Darzynkiewicz Z, Juan G, and Srour E F (2004) Differential Staining of DNA and RNA (2004). Current Protocols in Cytometry, Chapter 7:Unit 7.3).
- For viability analysis, cells were seeded into 96-well plates at 2×103-6×103 cells/well; the plated number of cells depended on cell size and rate of proliferation aiming for approximately 50% confluency. After seeding, the cells were allowed to attach for 24 hours incubated at 37° C. in a humidified 5% CO2 atmosphere.
- The treatments were performed using at least 6 different concentrations of a compound in 1:3 serial dilutions in DMSO such that the DMSO concentration in the cell medium was <1%. The cell cultures were incubated for an additional 96 hours in 5% CO2 incubator at 37° C. Treatments were performed in triplicate. Results were analyzed by CellTiter-Glo™ Luminescent Cell Viability Assay (Promega, cat. # G7571) according to the manufacturer's instructions using Spectra MAX Gemini Spectrophotometer (Molecular Devices).
- SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 100 nM and the concentrations of Compound I-5 were 2 μM and 4 accordingly. The observed EC50 values of paclitaxel were 8.1 nM when Compound I-5 was not present, 2.3 nM when Compound I-5 was present at a concentration of 2 and 0.2 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 3 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of paclitaxel were 2.7 nM when Compound I-7 was not present, 1.9 nM when Compound I-7 was present at a concentration of 2 μM, and 0.9 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 4 . - LNCap cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of paclitaxel were 3.2 nM when Compound I-5 was not present, 2.1 nM when Compound I-5 was present at a concentration of 2 μM, and 0.9 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 5 . - HCC827 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of paclitaxel were 4.2 nM when Compound I-7 was not present, 2.5 nM when Compound I-7 was present at a concentration of 3 μM, and 0.6 nM when Compound I-7 was present at a concentration of 6 μM. See
FIG. 6 . - A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of paclitaxel were 4.8 nM when Compound I-7 was not present, 2.5 nM when Compound I-7 was present at a concentration of 3 μM, and 0.7 nM when Compound I-7 was present at a concentration of 6 μM. See
FIG. 7 . - SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 μM, 4 μM, 8 μM, and 10 μM. The observed EC50 values of paclitaxel were 9.7 nM when Compound I-7 was not present, 9.4 nM when Compound I-7 was present at a concentration of 2 μM, 4.8 nM when Compound I-7 was present at a concentration of 4 μM, 4.7 nM when Compound I-7 was present at a concentration of 8 μM, and 5.2 nM when Compound I-7 was present at a concentration of 10 μM. See
FIG. 8 . - OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of paclitaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of paclitaxel were 3.3 nM when Compound I-7 was not present, 2.8 nM when Compound I-7 was present at a concentration of 3 μM, and 1.7 nM when Compound I-7 was present at a concentration of 6 μM. See
FIG. 9 . - SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 100 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of docetaxel were 2.85 nM when Compound I-5 was not present, 0.69 nM when Compound I-5 was present at a concentration of 2 and <0.015 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 10 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of docetaxel were 0.64 nM when Compound I-7 was not present, 0.38 nM when Compound I-7 was present at a concentration of 2 and 0.14 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 11 . - HCC827 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of docetaxel were 1.8 nM when Compound I-7 was not present, 0.6 nM when Compound I-7 was present at a concentration of 2 and 0.03 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 12 . - A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 5 nM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of docetaxel were 1.4 nM when Compound I-7 was not present, 0.6 nM when Compound I-7 was present at a concentration of 2 and 0.1 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 13 . - SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 4 μM and 8 μM. The observed EC50 values of docetaxel were 2.5 nM when Compound I-7 was not present, 1.5 nM when Compound I-7 was present at a concentration of 2 and 0.3 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 14 . - OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of docetaxel used in this assay was 10 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of docetaxel were 0.85 nM when Compound I-7 was not present, 0.52 nM when Compound I-7 was present at a concentration of 2 and <0.04 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 15 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vincristine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of vincristine were 1.1 nM when Compound I-5 was not present, 0.4 nM when Compound I-5 was present at a concentration of 2 and <0.04 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 16 . - H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vincristine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of vincristine were 1.5 nM when Compound I-5 was not present, 0.85 nM when Compound I-5 was present at a concentration of 2 and 0.35 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 17 . - SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vincristine used in this assay was 20 nM and the concentrations of Compound I-7 were 4 μM and 8 μM. The observed EC50 values of vincristine were 8.7 nM when Compound I-7 was not present, 2.1 nM when Compound I-7 was present at a concentration of 4 and 1.0 nM when Compound I-7 was present at a concentration of 8 μM. See
FIG. 18 . - OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vincristine used in this assay was 1 nM and the concentrations of Compound I-7 were 1 μM and 3 μM. The observed EC50 values of vincristine were 1.2 nM when Compound I-7 was not present, 0.8 nM when Compound I-7 was present at a concentration of 2 and 0.1 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 19 . - Vinorelbine
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of vinorelbine were 1.1 nM when Compound I-5 was not present, 0.4 nM when Compound I-5 was present at a concentration of 2 and <0.04 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 20 . - H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-5 were 2 μM and 4 μM. The observed EC50 values of vinorelbine were 9.5 nM when Compound I-5 was not present, 5.2 nM when Compound I-5 was present at a concentration of 2 and 2.1 nM when Compound I-5 was present at a concentration of 4 μM. See
FIG. 21 . - OVCAR3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vinorelbine used in this assay was 10 nM and the concentrations of Compound I-7 were 1 μM and 3 μM. The observed EC50 values of vinorelbine were 2.4 nM when Compound I-7 was not present, 2.4 nM when Compound I-7 was present at a concentration of 1 and 0.1 nM when Compound I-7 was present at a concentration of 3 μM. See
FIG. 22 . - SK-OV-3 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vinorelbine used in this assay was 40 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of vinorelbine were 15.1 nM when Compound I-7 was not present, 10.1 nM when Compound I-7 was present at a concentration of 2 and 4.7 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 23 . - A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of vinorelbine used in this assay was 50 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of vinorelbine were 27 nM when Compound I-7 was not present, 16 nM when Compound I-7 was present at a concentration of 2 and 6 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 24 . - H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of BI2536 were 46.3 nM when Compound I-7 was not present, 17.3 nM when Compound I-7 was present at a concentration of 2 and <0.04 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 25 . - PANC1 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of BI2536 were 7.3 nM when Compound I-7 was not present, 4.4 nM when Compound I-7 was present at a concentration of 2 and 2.5 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 26 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of BI2536 were 6.2 nM when Compound I-7 was not present, 4.1 nM when Compound I-7 was present at a concentration of 2 and 1.7 nM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 27 . - A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of BI2536 used in this assay was 50 nM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of BI2536 were 6.2 nM when Compound I-7 was not present, 4.1 nM when Compound I-7 was present at a concentration of 3 and 1.7 nM when Compound I-7 was present at a concentration of 6 μM. See
FIG. 28 . - H1975 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of GSK461364 used in this assay was 10 μM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of GSK461364 were 1.9 μM when Compound I-7 was not present, 0.97 μM when Compound I-7 was present at a concentration of 2 and 0.58 μM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 29 . - PANC1 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of GSK461364 used in this assay was 10 μM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of GSK461364 were 0.5 μM when Compound I-7 was not present, 0.3 μM when Compound I-7 was present at a concentration of 2 and 0.2 μM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 30 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of GSK461364 used in this assay was 10 μM and the concentrations of Compound I-7 were 2 μM and 4 μM. The observed EC50 values of GSK461364 were 0.43 μM when Compound I-7 was not present, 0.24 μM when Compound 1-7 was present at a concentration of 2 and 0.12 μM when Compound I-7 was present at a concentration of 4 μM. See
FIG. 31 . - A549 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The highest concentration of GSK461364 used in this assay was 1 μM and the concentrations of Compound I-7 were 3 μM and 6 μM. The observed EC50 values of GSK461364 were 1.2 μM when Compound I-7 was not present, 0.5 μM when Compound I-7 was present at a concentration of 3 and 0.2 μM when Compound I-7 was present at a concentration of 6 μM. See
FIG. 32 . - DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of paclitaxel, Compound I-7, or both paclitaxel and Compound I-7 are present are shown in
FIG. 33 . - In this experiment it was demonstrated that exposure of DMS273 cells to paclitaxel does not result in pharmacological quiescence as the fraction of cells in G0 phase of the cell cycle was similar with or without paclitaxel. It was also demonstrated that combination of Compound I-7 with paclitaxel strongly affected the cell cycle distribution of DMS273 cells and resulted in significant reduction of the fraction of cells in G0. Moreover, the cytotoxicity of the combination was significantly higher than that of paclitaxel alone as evidenced by significant increases in fraction of apoptotic cells observed as sub-G0 population.
- The cell cycle distributions of normally proliferating DMS273 cells incubated in regular growth medium (FBS+) and DMS273 cells pre-incubated in serum free media (FBS−) are shown for comparison.
- SW620 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of paclitaxel, Compound I-7, or both paclitaxel and Compound I-7 are present are shown in
FIG. 34 . - In this experiment it was demonstrated that exposure of SW620 cells to paclitaxel does not result in pharmacological quiescence as the fraction of cells in G0 phase of the cell cycle was similar with or without paclitaxel in cells incubated in growth medium (FBS+). It was also demonstrated that combination of Compound I-7 with paclitaxel strongly affected the cell cycle distribution of SW620 cells and resulted in significant reduction of the fraction of cells in G0. Moreover, the cytotoxicity of the combination was significantly higher than that of paclitaxel alone as evidenced by significant increases in fraction of apoptotic cells observed as sub-G0 population.
- The cell cycle distributions of normally proliferating SW620 cells incubated in regular growth medium (FBS+) and SW620 cells pre-incubated in serum free media (FBS−) are shown for comparison.
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of vincristine, Compound I-7, or both vincristine and Compound I-7 are present are shown in
FIG. 35 . - In this experiment it was demonstrated that exposure of DMS273 cells to vincristine does not result in pharmacological quiescence as the fraction of cells in G0 phase of the cell cycle was similar with or without vincristine in cells incubated in growth medium (FBS+). It was also demonstrated that combination of Compound I-7 with vincristine strongly affected the cell cycle distribution of DMS273 cells and resulted in significant reduction of the fraction of cells in G0. Moreover, the cytotoxicity of the combination was significantly higher than that of vincristine alone as evidenced by significant increases in fraction of apoptotic cells observed as sub-G0 population.
- The cell cycle distributions of normally proliferating DMS273 cells incubated in regular growth medium (FBS+) and DMS273 cells pre-incubated in serum free media (FBS−) are shown for comparison.
- DMS273 cells were cultured, treated, and analyzed as described in Examples 1 and 2. The results when different concentrations of vinorelbine, Compound I-7, or both vinorelbine and Compound I-7 are present are shown in
FIG. 36 . - In this experiment it was demonstrated that exposure of DMS273 cells to vinorelbine does not result in pharmacological quiescence. It was also demonstrated that combination of Compound I-7 with vinorelbine affected the cell cycle distribution of DMS273 cells and resulted in significant reduction of the fraction of cells in G0. Moreover, the cytotoxicity of the combination was significantly higher than that of vinorelbine alone as evidenced by significant increases in fraction of apoptotic cells observed as sub-G0 population.
- The cell cycle distributions of normally proliferating DMS273 cells incubated in regular growth medium (FBS+) and DMS273 cells pre-incubated in serum free media (FBS−) are shown for comparison.
- The SW620 cells were cultured and treated as described in Example 1. For propidium iodide (PI) staining, manufacturer's protocol supplied with the Guava Cell Cycle Reagent for Flow Cytometry (EMD Millipore) was followed. The measurements were performed with Guava PCA-96 flow cytometer (EMD Millipore) using the green laser for excitation at 535 nm and monitoring emission at 617 nm.
- The results when different concentrations of AZ191 were present are shown in
FIG. 37 . The data are average of two replicates. - The SW620 cells were cultured, treated, and analyzed as described in Examples 1. For propidium iodide (PI) staining, manufacturer's protocol supplied with the Guava Cell Cycle Reagent for Flow Cytometry (EMD Millipore) was followed. The measurements were performed with Guava PCA-96 flow cytometer (EMD Millipore) using the green laser for excitation at 535 nm and monitoring emission at 617 nm.
- The results when different concentrations of Compound I-7 were present are shown in
FIG. 38 . The data are average of two replicates. - In these experiments, SW620 cells were incubated for 24 hours in FBS− media, which contained different concentrations of either AZ191 or Compound I-7. Under these conditions, exposure to AZ191 led to no decrease in fraction of cells in quiescent state (G0) based on no observed change in the fraction of cells G0+G1 phase. Under the same conditions, exposure to same or lower concentrations of Compound I-7 led to a significant decrease in fraction of cells in quiescent state (G0) based on the significant decrease in the fraction of cells G0+G1 phase.
- AZ191 inhibits DYRK1B at 17 nM (Ashford A L, Oxley D, Kettle J, Hudson K, Guichard S, Cook S J, Lochhead P A (2014) A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3beta to phosphorylate cyclin D1 at Thr(286), not Thr(288). Biochemical Journal 457, 43-56).
- In this experiment, it was demonstrated that not all DYRK1 inhibitors are effective against quiescent cancer cells.
- While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (32)
1. A method for treating a subject having a neoplasm, the method comprising administering to the subject, sequentially or concomitantly,
(a) a DYRK1 inhibitor which inhibits DYRK1A or DYRK1B kinase activity with an IC50 of 100 nM or lower in biochemical assays, and reduces the fraction of quiescent cancer cells (in vitro or in vivo) that would otherwise be found in the absence of such inhibitor by at least 10%; and
(b) administering to the subject an inhibitor of mitosis.
2. The method of claim 1 , further comprising administering to the subject an effective amount of radiation therapy.
3. The method of claim 1 , wherein the neoplasm being treated is either a primary or a metastatic cancer selected from biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, thyroid cancer, uterine cancer, bladder cancer, breast cancer, colorectal cancer, ovarian cancer, and prostate cancer.
4. The method of claim 1 , wherein the neoplasm being treated is either a primary or metastatic colon cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, small cell lung cancer, or pancreatic cancer.
5. The method of claim 1 , wherein the inhibitor of mitosis is a taxane, a vinca alkaloid, or a PLK1 inhibitor.
6. The method of claim 1 , wherein the inhibitor of mitosis is selected from BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
7. The method of claim 1 , wherein the inhibitor of mitosis is selected from vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.
8. The method of claim 1 , wherein the inhibitor of mitosis is vintafolide.
9. The method of claim 1 , wherein the inhibitor of mitosis is selected from a list of BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
10. The method of claim 1 , wherein the DYRK1 inhibitor is selected from I-1, I-2, I-3, I-4, I-5, I-6, and I-7.
11. A method for treating a subject having a neoplasm, the method comprising administering to the subject, sequentially or concomitantly, a DYRK1 inhibitor and administering to the subject an inhibitor of mitosis, wherein the EC50 value of the inhibitor of mitosis is at least 20% lower in the combination treatment when compared to the same treatment with the inhibitor of mitosis alone, as determined in cell-based assays.
12. The method of claim 11 , wherein the DYRK1 inhibitor has a Formula I
or a pharmaceutically acceptable salt or solvate thereof, wherein
R1 is a substituted or unsubstituted C1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl;
R2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO2, NHC(O)C1-4 alkyl, C1-4 alkyl, OH, OC1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S.
13. The method of claim 11 , further comprising administering to the subject an effective amount of radiation therapy.
14. The method of claim 11 , wherein the neoplasm being treated is either a primary or metastatic cancer selected from biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, thyroid cancer, uterine cancer, bladder cancer, breast cancer, colorectal cancer, ovarian cancer, and prostate cancer.
15. The method of claim 11 , wherein the neoplasm being treated is either a primary or metastatic colon cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, small cell lung cancer, or pancreatic cancer.
16. The method of claim 11 , wherein the inhibitor of mitosis is a taxane, a vinca alkaloid, or a PLK1 inhibitor.
17. The method of claim 11 , wherein the inhibitor of mitosis is selected from BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
18. The method of claim 11 , wherein the inhibitor of mitosis is selected from a list of vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.
19. The method of claim 11 , wherein the inhibitor of mitosis is vintafolide.
20. The method of claim 11 , wherein the inhibitor of mitosis is selected from BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
21. The method of claim 11 , wherein the DYRK1 inhibitor is selected from I-1, I-2, I-3, I-4, I-5, I-6, and I-7.
22. A method for treating a subject having a neoplasm, the method comprising administering to the subject, sequentially or concomitantly, a DYRK1 inhibitor and administering to the subject an inhibitor of mitosis, wherein the combination treatment increases fraction of apoptotic cells in a treated population as compared to either agent alone by at least by 2-fold, as determined by fraction of sub-G0 cells by a FACS assay.
23. The method of claim 22 , wherein the DYRK1 inhibitor has a Formula I
or a pharmaceutically acceptable salt or solvate thereof, wherein,
R1 is a substituted or unsubstituted C1-8 alkyl, a substituted or unsubstituted phenyl, or a substituted or unsubstituted benzyl;
R2 is phenyl, optionally substituted with up to four groups independently selected from halo, CN, NO2, NHC(O)C1-4 alkyl, C1-4 alkyl, OH, OC1-4 alkyl, wherein two adjacent groups and their intervening carbon atoms may form a 5- to 6-membered ring containing one or more heteroatoms selected from N, O, or S.
24. The method of claim 22 , further comprising administering to the subject an effective amount of radiation therapy.
25. The method of claim 22 , wherein the neoplasm being treated is a either a primary or metastatic cancer selected from biliary cancer, brain cancer, breast cancer, cervical cancer, colon cancer, gastric cancer, kidney cancer, head and neck cancer, leukemia, liver cancer, lung cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, sarcoma, skin cancer, testicular cancer, thyroid cancer, uterine cancer, bladder cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, and prostate cancer.
26. The method of claim 22 , wherein the neoplasm being treated is either a primary or metastatic colon cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, small cell lung cancer, pancreatic cancer.
27. The method of claim 22 , wherein the inhibitor of mitosis is a taxane, a vinca alkaloid, or a PLK1 inhibitor.
28. The method of claim 22 , wherein the inhibitor of mitosis is selected from BMS-188796, BMS-188797, cabazitaxel, DEP cabazitaxel, docetaxel, larotaxel (XRP9881, RPR109881), paclitaxel, taxoprexin (DHA-paclitaxel), and tesetaxel (DJ-927).
29. The method of claim 22 , wherein the inhibitor of mitosis is selected from a list of vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.
30. The method of claim 22 , wherein the inhibitor of mitosis is vintafolide.
31. The method of claim 22 , wherein the inhibitor of mitosis is selected from BI-2536, GSK461364, GW843682X, HMN-214 and HMN-176, MLN-0905, NMS-P937, rigosertib, Ro3280, SBE 13, and volasertib.
32. The method of claim 22 , wherein the DYRK1 inhibitor is selected from I-1, I-2, I-3, I-4, I-5, I-6, and I-7.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/436,305 US20190290651A1 (en) | 2016-04-15 | 2019-06-10 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
US17/558,204 US20220110941A1 (en) | 2016-04-15 | 2021-12-21 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662323583P | 2016-04-15 | 2016-04-15 | |
US15/488,143 US10314843B2 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
US16/436,305 US20190290651A1 (en) | 2016-04-15 | 2019-06-10 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/488,143 Division US10314843B2 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/558,204 Continuation US20220110941A1 (en) | 2016-04-15 | 2021-12-21 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190290651A1 true US20190290651A1 (en) | 2019-09-26 |
Family
ID=60039311
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/488,143 Active US10314843B2 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
US16/436,305 Abandoned US20190290651A1 (en) | 2016-04-15 | 2019-06-10 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
US17/558,204 Pending US20220110941A1 (en) | 2016-04-15 | 2021-12-21 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/488,143 Active US10314843B2 (en) | 2016-04-15 | 2017-04-14 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/558,204 Pending US20220110941A1 (en) | 2016-04-15 | 2021-12-21 | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis |
Country Status (11)
Country | Link |
---|---|
US (3) | US10314843B2 (en) |
EP (1) | EP3443351A4 (en) |
JP (1) | JP7278776B2 (en) |
KR (2) | KR20230020560A (en) |
CN (1) | CN109313197A (en) |
AU (2) | AU2017248807A1 (en) |
BR (1) | BR112018071023A2 (en) |
CA (1) | CA3020978A1 (en) |
IL (2) | IL292475A (en) |
MX (2) | MX2018012508A (en) |
WO (1) | WO2017181087A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2018012511A (en) | 2016-04-15 | 2019-07-08 | Felicitex Therapeutics Inc | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2475368T3 (en) * | 2009-09-11 | 2015-03-09 | Amgen Inc | N- (4 - ((3- (2-amino-4-pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-PHTHALAZINAMIN for use in the treatment of cancer, WHICH IS rESISTANT TO antimitotics |
US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
CN103797002B (en) * | 2011-08-19 | 2017-02-22 | 迪亚克森海特公司 | Dyrk1 inhibitors and uses thereof |
FR2993317B1 (en) | 2012-07-16 | 2014-08-15 | Snecma | TURBOMACHINE HOUSING IN COMPOSITE MATERIAL AND METHOD OF MANUFACTURING THE SAME |
JP2015534584A (en) | 2012-10-10 | 2015-12-03 | フェリシテックス・セラピューティクス,インコーポレイテッド | Cancer treatment by targeting quiescent cancer cells |
MA38656A1 (en) * | 2013-06-11 | 2018-05-31 | Bayer Pharma AG | Combinations for the treatment of cancer comprising an inhibitor of the mps-1 kinase and a mitosis inhibitor |
CA2854542A1 (en) * | 2013-06-18 | 2014-12-18 | 4Sc Discovery Gmbh | Method of inhibiting dyrk1b |
WO2015116696A1 (en) | 2014-01-28 | 2015-08-06 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
MA39763A (en) * | 2014-03-20 | 2017-01-25 | Samumed Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
US20170304313A1 (en) | 2014-10-06 | 2017-10-26 | Novartis Ag | Therapeutic Combination For The Treatment Of Cancer |
NZ739867A (en) * | 2015-07-23 | 2023-06-30 | Calgent Biotechnology Co Ltd | Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases |
MX2018012511A (en) | 2016-04-15 | 2019-07-08 | Felicitex Therapeutics Inc | Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors. |
-
2017
- 2017-04-14 JP JP2018554360A patent/JP7278776B2/en active Active
- 2017-04-14 KR KR1020237002817A patent/KR20230020560A/en not_active Application Discontinuation
- 2017-04-14 AU AU2017248807A patent/AU2017248807A1/en not_active Abandoned
- 2017-04-14 WO PCT/US2017/027734 patent/WO2017181087A1/en active Application Filing
- 2017-04-14 MX MX2018012508A patent/MX2018012508A/en unknown
- 2017-04-14 CN CN201780037724.5A patent/CN109313197A/en active Pending
- 2017-04-14 EP EP17783296.1A patent/EP3443351A4/en active Pending
- 2017-04-14 IL IL292475A patent/IL292475A/en unknown
- 2017-04-14 CA CA3020978A patent/CA3020978A1/en active Pending
- 2017-04-14 US US15/488,143 patent/US10314843B2/en active Active
- 2017-04-14 KR KR1020187033030A patent/KR102494172B1/en active IP Right Grant
- 2017-04-14 BR BR112018071023A patent/BR112018071023A2/en not_active Application Discontinuation
-
2018
- 2018-10-11 IL IL262325A patent/IL262325B/en unknown
- 2018-10-12 MX MX2022012146A patent/MX2022012146A/en unknown
-
2019
- 2019-06-10 US US16/436,305 patent/US20190290651A1/en not_active Abandoned
-
2021
- 2021-12-21 US US17/558,204 patent/US20220110941A1/en active Pending
-
2023
- 2023-08-08 AU AU2023214240A patent/AU2023214240A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017248807A1 (en) | 2018-10-25 |
KR102494172B1 (en) | 2023-02-02 |
MX2022012146A (en) | 2022-10-21 |
CA3020978A1 (en) | 2017-10-19 |
CN109313197A (en) | 2019-02-05 |
BR112018071023A2 (en) | 2019-02-05 |
MX2018012508A (en) | 2019-07-08 |
WO2017181087A1 (en) | 2017-10-19 |
JP2019511553A (en) | 2019-04-25 |
IL262325A (en) | 2018-11-29 |
IL262325B (en) | 2022-06-01 |
KR20230020560A (en) | 2023-02-10 |
US10314843B2 (en) | 2019-06-11 |
AU2023214240A1 (en) | 2023-08-24 |
US20220110941A1 (en) | 2022-04-14 |
KR20180130575A (en) | 2018-12-07 |
IL292475A (en) | 2022-06-01 |
EP3443351A4 (en) | 2019-12-18 |
US20170296542A1 (en) | 2017-10-19 |
EP3443351A1 (en) | 2019-02-20 |
JP7278776B2 (en) | 2023-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220110940A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors | |
CN104363913A (en) | CDK8/CDK19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
US20220168333A1 (en) | Combination Treatment for Hematological Cancers | |
AU2023214240A1 (en) | Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis | |
US20230226061A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
WO2023140846A1 (en) | Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway | |
US10512631B2 (en) | Chalcone compounds | |
Kang et al. | Targeting MutT homolog 1 (MTH1) for breast cancer suppression by a novel MTH1 inhibitor MA-24 with tumor-selective toxicity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |